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Drug abuse and dependence are among the most challenging public health issues 
facing America today. The acute treatment of drugs of abuse such as psychostimulants 
(Trantham-Davidson and Lavin, 2004) and opiates (Harris and Williams, 1991) produce 
transient changes in cellular activity and synaptic signaling. Repeated drug treatment, 
however, results in persistent cellular and behavioral changes, such as altered dendritic 
morphology and behavioral sensitization (Robinson and Kolb, 1999b). Synaptic changes 
in the brain are posited to underlie a repertoire of drug-induced persistent behaviors, 
including sensitization, psychosis and relapse. Direct evidence of drug-induced synaptic 
plasticity, however, has not been demonstrated. The present studies were designed to 
examine cholinergic neurons and synaptic rewiring as potential neural substrates involved 
in acute and chronic drug exposure. The proposed studies tested the hypotheses that 1) 
cholinergic interneurons within the nucleus accumbens (NAcc) are activated by the acute 
 vii
self-administration of cocaine, 2) dopamine (DA) D5 and D2 receptors localized on 
cholinergic interneurons potentially undergo cocaine-induced neuroadaptation, and 3) 
repeated administration of cocaine leads to an increase, while repeated administration of 
morphine leads to a decrease, in the number of synapses within the NAcc, whereas an 
increase in the number of synapses occurs in the NAcc core of animals exhibiting 
behavioral sensitization. 
These studies revealed that accumbal cholinergic interneurons are activated by 
acute cocaine self-administration and elucidate the specific localization of DA receptor 
subtypes, D5 and D2, on these cells, suggesting their potential role in mediating drug-
induced DA changes within the NAcc. The final study provided the first ultrastructural 
evidence that an increase in the number of excitatory synapses in the NAcc shell occurs 
following 4-weeks of cocaine and morphine treatment followed by 3 weeks abstinence 
and that cocaine sensitization is associated with an increase in the number of excitatory 
synapses in the NAcc core. These findings provide the groundwork for future studies 
examining the precise cellular and synaptic substrates underlying a repertoire of drug-
induced behaviors that contribute to the persistence of addiction. Improved 
pharmacotherapeutic and behavioral treatments can then target the specific cellular and 
synaptic microcircuitry critically involved in the different stages of drug abuse and 
dependence. 
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Chapter 1: Introduction 
Drug abuse and dependence are two of the most challenging public health issues 
facing America today. The Office of National Drug Control Policy estimates illicit drug 
trafficking and abuse costs the United States 180.9 billion dollars each year (National 
Drug Intelligence Center, 2006). Furthermore, drug abuse takes an enormous emotional 
toll on the families struggling to help the people they love. Research studies aimed at 
identifying possible neuronal substrates and mechanisms underlying drug abuse and 
dependency are helping to combat this national health problem. The better we understand 
the cellular circuits and neuroadaptive changes underlying compulsive drug use, the 
better chance we will have at treating drug dependency successfully. The following 
research studies attempt to broaden the current knowledge surrounding the effects of 
acute and chronic drug treatment by shedding light on potential neuronal substrates 
mediating the actions of addictive drugs in the brain. 
Drugs of abuse activate pleasure centers in the brain and increase levels of 
dopamine (DA), the neurotransmitter responsible for the euphoric effects or “high” 
described by many cocaine users (Volkow et al., 1997). Acute drug administration leads 
to increased DA release and neuronal activation in the NAcc (Moratalla et al., 1996; 
Gerrits et al., 2002). Recently, however, DA’s role in drug abuse and dependency has 
become increasingly unclear, as more studies are beginning to show that animals 
continue to show preference for drugs after DA signaling has been pharmacologically 
blocked, destroyed, or genetically inactivated (Berridge and Robinson, 1998; Robinson et 
al., 2005). The effects of drug administration on glutamatergic signaling in key drug-
related brain regions are receiving more attention as a result of the significant role the 
PFC plays in self-administration and drug-seeking behavioral paradigms (Sun and Rebec, 
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2006). Thus, the search for one neurotransmitter acting at the center of drug addiction 
may be too simplistic an approach. Therefore it is likely that the contribution of both 
neurotransmitter systems (i.e. DA and glutamate) mediate the actions of drugs of abuse, 
utilizing the integrative properties of the cells located in these critical drug-associated 
brain regions.  
Repeated drug use can lead to long-lasting molecular and cellular changes in the 
brain detectable even after drug cessation (Carlezon et al., 1998; Robinson and Kolb, 
1999b; Vanderschuren and Kalivas, 2000; Shaw-Lutchman et al., 2002; Norrholm et al., 
2003; Chao and Nestler, 2004). These neuroadaptive changes presumably underlie the 
persistent behavioral changes observed following chronic drug treatment (Robinson and 
Kolb, 1999a, b; Bibb et al., 2001; Wang et al., 2004; Chen and Chen, 2005). Although, 
when these molecular changes are mapped along the same time course as behavioral 
changes, studies show that the behaviors outlast the molecular changes. For example, one 
of the longest lasting changes in the brain detected following repeated drug treatment is 
the accumulation of delta FosB, but once drug treatment ceases, delta FosB protein levels 
return to baseline after 6-8 weeks. Drug-related behavioral changes, such as sensitization, 
can persist for years (Paulson et al., 1991), long after delta FosB levels have subsided. 
Therefore, a change in synapse number, a long-lasting neuroadaptive change in the brain 
which has been previously found to occur following learning paradigms, may help 
explain the cellular mechanisms underlying persistent drug-induced behaviors. 
The following studies were designed to address questions that remain unanswered 
in the literature regarding acute and chronic effects of drug administration on 
neuroplasticity. Critical brain areas and molecular changes involved in addiction have 
been previously identified, but specific cell types within these brain regions and their role 
in addiction have not been previously examined. Therefore, the first two studies 
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comprised in this dissertation examine a specific cell population in the NAcc, the 
cholinergic interneurons, a group of cells in the NAcc that have remained largely 
overlooked in drug addiction research. Furthermore, these studies provide the first 
evidence of synaptic changes in the NAcc associated with repeated drug treatment. While 
key brain areas and molecular changes following long-term drug administration have 
been identified, cellular neuroadaptations underlying drug-induced persistent behaviors 
remain unclear. It has been posited that such long-lasting behaviors may be explained by 
synaptic reorganization. Thus, synaptic changes resulting from long-term drug 
administration, as reported in the final chapter of this dissertation, may be one type of 
neural substrate mediating long-lasting drug-related persistent behaviors. The following 
studies were designed to test the hypotheses that 1) cholinergic interneurons in the NAcc 
shell and core are differentially activated by the acute self-administration of cocaine, 2) 
DA D5 and DA D2 receptors are localized on cholinergic interneurons of the NAcc shell 
and core and these DA receptors potentially undergo cocaine-induced neuroadaptation, 3) 
repeated administration of cocaine leads to an increase in the number of synaptic 
connections within the NAcc shell and core, while repeated administration of morphine 
leads to a decrease in the number of synaptic connections within the NAcc shell and core 
and 4) the increase in the number of synapses in the NAcc core are associated with 
animals exhibiting behavioral sensitization. 
The remaining pages of this chapter provide the groundwork for the hypotheses 
presented in the studies discussed in chapters 2 through 5. The first sections of this 
introduction present common drug-related neurocircuits that are known to undergo 
neuroadaptive changes following the administration of most drugs of abuse, including 
psychostimulants and opiates, and the neuronal populations that make up these 
neurocircuits. Because the primary neuronal pathways activated by drugs of abuse 
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involve dopaminergic systems, the next sections discuss DA receptor families and 
subtypes and the intracellular cascades they activate, including activation of immediate 
early genes (IEGs), as a result of DA binding. These receptors, although not solely 
responsible for the long-lasting changes resulting from cocaine and morphine treatment, 
undoubtedly play a role in drug abuse and dependence. Lastly, the final sections present a 
review of the literature on the molecular actions of cocaine and morphine and the effects 
of long-term use. Specifically, these sections address the potential consequences of drug 
use and the structural neuroadaptations within the NAcc potentially underlying persistent 
drug-induced behaviors.    
1.1 Mesolimbic Dopamine Pathway 
The mesolimbic DA pathway consists of projections from DA neurons of the 
ventral tegmental area (VTA) to the NAcc (Fig. 1.1) (Bozarth, 1991). This neuronal 
circuit is the primary pathway underlying reward and reinforcement (Di Chiara and 
Imperato, 1988). The VTA also sends DA projections to the cortex, called the 
mesocortical DA pathway (Bozarth, 1991). While drugs of abuse have the ability to 
modulate many different neurotransmitter systems in the brain, increases in DA 
neurotransmission in the NAcc following the initial stages of drug intake is regularly 
observed. In fact, if the DA-containing cell bodies in the VTA are destroyed with 6-
OHDA, animals significantly reduce their drug-intake or completely stop responding for 
drug administration (Roberts and Koob, 1982). Interestingly, if the postsynaptic actions 
of DA are blocked in the NAcc, via DA receptor antagonists, animals trained to self-
administer for drugs will increase their drug intake, presumably, to compensate for the 
disregulation of DA (Stellar and Corbett, 1989). Recently, however, the idea of a central 
role for DA in drug abuse and dependence is being challenged. Evidence continues to 
accumulate which suggests a significant role for glutamate (in addition to DA) in drug-





Figure 1.1. Mesolimbic and mesocortical projections. Simplified diagram showing 
dopaminergic (black arrows) and glutamatergic (gray arrows) projections within the 
mesolimbic (VTA-NAcc) and mesocortical (VTA-PFC) DA pathways, as well as 
GABAergic projections (dashed arrow).   
VTA
 
1.2 Nucleus Accumbens 
The NAcc is also known as the ventral striatum. This region of the striatum has 
been shown to possess many of the same cell types found in the dorsal striatum, namely 
the medium spiny projection neurons (MSNs), large aspiny cholinergic interneurons, as 
well as several types of inhibitory GABAergic interneurons (Kawaguchi, 1997).  The 
NAcc as a whole is a neuroanatomically complex structure, integrating both limbic and 
motor information from mesencephalic DA sources and interconnected with other brain 
areas. More importantly, neuroanatomical and neurochemical studies have elucidated the 
heterogeneous nature of the NAcc shedding light on the range of functions of this 
particular brain region. The distinctions between the neuroanatomical, neurochemical and 
neuronal functions are outlined below.    
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1.2.1 Shell and Core Subcompartments of the Nucleus Accumbens 
The NAcc is divided into two subcompartments, the shell and core. The shell 
compartment of the NAcc receives dense dopaminergic innervation from A10 DA 
neurons of the VTA (Voorn et al., 1986; Brog et al., 1993), while the core compartment 
of the NAcc receives its major source of DA from A9 DA neurons of the substantia nigra 
pars compacta (SNc) (Nirenberg et al., 1996). Such differences in dopaminergic 
innervation, as well as their afferent and efferent connections with other brain regions, 
account for the functional differences between these two subcompartments (Zahm and 
Heimer, 1990; Heimer et al., 1991; Di Chiara, 2002). Heimer et al. (1991) masterfully 
explored the neuroanatomical connections of the shell and core highlighting the efferent 
connections of the shell with the extended amygdala (limbic) and the core with the 
entopeduncular nucleus (motor). Furthermore, glutamatergic projections from the 
infralimbic PFC innervate the NAcc shell, whereas projections from the prelimbic PFC 
innervate the NAcc core (Ding et al., 2001). Moreover, the shell and core subregions can 
also be distinguished using specific neurochemical markers. For example, 
immunoreactivity for calbindin, used to distinguish between the patch (limbic) and matrix 
(motor) compartments, further supports the notion that the shell is more involved in 
limbic-related functions (Gerfen, 1984) as opposed to the core, which has been strongly 
linked to motor-related functions. However, upon closer examination, each subregion 
shows inhomogeneous staining along the rostral-caudal as well as the medial-lateral axes 
(Voorn et al., 1986; Meredith et al., 1992; Meredith, 1999), thereby adding to the 
neuroanatomical complexity within each subcompartment of the NAcc.  
Drugs of abuse differentially activate these two divisions of the NAcc. Studies 
suggest that the NAcc shell plays an important role in incentive arousal because 
excitotoxic lesions to this brain area interfere with conditioned reinforcement (Parkinson 
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et al., 1999). Alternatively, excitotoxic lesions to the NAcc core disrupt instrumental 
performance (Corbit et al., 2001). Dopamine release in the NAcc shell is greater than in 
the core, with acute (Pontieri et al., 1995) administration of cocaine (independent of 
whether the drugs are self-administered or experimenter-administered). Caffeine, a non-
addictive drug, does not produce the same DA response in the NAcc, thus, DA release in 
the shell is specific to drug-rewards (Acquas et al., 2002). Furthermore, chronically (15 
days) self-administered cocaine shows an increase in DA in both the NAcc shell and 
core, with significantly higher levels of DA in the shell (Di Chiara et al., 2004). 
Additionally, pharmacological studies suggest that drug-induced changes in glutamate 
release in the NAcc and drug-mediated changes in behavior depend on dopaminergic 
systems (Reid and Berger, 1996; Reid et al., 1997). More recently, at the behavioral level, 
changes in the morphology of cells in the NAcc core have been correlated with 
behavioral sensitization (Li et al., 2004).  
1.2.2 Medium Spiny Projection Neurons of the Nucleus Accumbens 
Medium spiny projection neurons (MSNs) are the major output neurons of the 
NAcc, making up 95% of the total striatal cell population. These GABAergic neurons 
project to the ventral pallidum, entopeduncular nucleus and the mesencephalon (Heimer 
et al., 1991). They typically alternate between two electrical states, the Up state (i.e. 
depolarized state) and the Down state (i.e. polarized state), where action potentials only 
arise during the Up state (Bennett et al., 2000). Their cell bodies range in size from 15-20 
microns and these cells have dendrites that can extend up to 500 microns. Dendrites of 
MSNs are spine-free for the first 20 microns and then are covered in spines up to the 
terminal tips of the dendrites (Wilson and Groves, 1980). The highest density of spines 
occurs at approximately halfway along the length of the dendrite, about 40 to 60 microns 
away from the cell body (Meredith et al., 1992). These cells receive glutamatergic 
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(excitatory) inputs from the prefrontal cortex, thalamus, hippocampus, and the amygdala 
primarily onto the heads of their dendritic spines. Dopaminergic afferents also synapse 
onto the spines of these neurons, although these synapses are typically observed on the 
necks of the spines, dendritic shafts and sometimes the cell body (Zahm, 1992). 
Differences in the morphology of MSNs exist across the two compartments of the NAcc 
shell and core. For example, MSNs in the shell are smaller than cells in the core and have 
fewer dendritic branches as well as a lower spine density (Meredith et al., 1992). 
1.2.3 Aspiny Cholinergic Interneurons of the Nucleus Accumbens 
The cholinergic interneurons of the NAcc are some of the largest cells in this 
brain region. These interneurons can be identified using antibodies directed against 
choline acetyltransferase (ChAT), an enzyme used to synthesize acetylcholine (ACh). 
Cholinergic interneurons make up 1-2% of the total striatal cell population, and have 
large somata (20-50 µm) and extensive dendritic trees that extend up to 1 mm in length. 
These interneurons are also characterized by bifurcating varicose axons that form a dense 
axonal plexus (Wilson et al., 1990). The large dendritic and axonal fields allow these 
cells to integrate a variety of inputs over long distances within the NAcc. Although these 
cells typically do not have spines on their dendrites, spine-like appendages are sometimes 
observed on distal portions of their dendrites (Wilson et al., 1990). Furthermore, 
electrophysiological studies have shown that cholinergic interneurons have resting 
potentials that are close to threshold (i.e. readily excitable), and these cells typically fire 
in an irregular tonic pattern (Wilson et al., 1990). These cells are also shown to receive 
direct synaptic contact from the thalamus (Lapper and Bolam, 1992). Other glutamatergic 
brain areas that innervate the NAcc include the PFC, amygdala, and the hippocampus 
(Kalivas, 2004), which may also form synapses onto these cells. Thus, it has been 
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suggested that these cells may specialize in mediating information from the thalamus to 
the NAcc.  
1.3  Dopamine Receptors 
The DA receptor family is a group of five unique metabotropic, or G-protein-
coupled, receptors (D1, D2, D3, D4, and D5) with seven transmembrane regions. These 
receptors are divided into two distinct subfamilies, the DA D1-like receptors (D1 and D5) 
and the DA D2-like receptors (D2, D3 and D4). Dopamine D1 receptors are characterized 
by their ability to activate adenylyl cyclase (AC), while DA D2 receptors inhibit the 
stimulation of AC (Missale et al., 1998). Such functional differences are typically 
attributed to differences in structure between the two receptor families. One of the more 
prominent differences between the receptor subfamilies is the length of their third 
intracellular loop and carboxyl terminal tail. For example, D1-like receptors have a short 
third intracellular loop and a long carboxyl terminal tail, while D2-like receptors have 
long third intracellular loops and a short carboxyl terminal tail. The third intracellular 
loop of DA receptors are known to couple to specific types of G proteins (inhibitory 
versus stimulatory), thereby accounting for some of their functional differences (Ilani et 
al., 2002). When DA binds to one of these receptors, the receptor undergoes a 
conformational change. This conformational change leads to activation of the G-protein 
and subsequent second messenger proteins. One other distinguishing property between 
the two receptor families is the presence of introns in the receptor genes (Civelli et al., 
1993). Dopamine D1 receptor genes (both D1 and D5 receptors) lack introns. The DA D2 
receptor family contains introns in its receptor genes, and this is believed to be 
responsible for the generation of receptor variants, such as the long and short chain 
variants of the DA D2 receptor subtype (O'Dowd, 1993). Interestingly, although these 
receptor subfamilies exhibit unique structural differences and opposing functions, upon 
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activation via DA binding, these receptors will in some cases produce a synergistic effect. 
Thus, DA receptors are important neuronal substrates, and prove to be critical targets 
when treating a variety of neurological disorders including schizophrenia, Parkinson’s 
disease and drug dependency.  
1.3.1  Dopamine D1 Receptor Subfamily 
The DA D1 receptor family consists of DA D1 and DA D5 receptor subtypes. 
These receptors have highly conserved amino acid sequences, sharing 80% homology in 
their transmembrane domains. While these two receptor subtypes have similar 
pharmacological properties, they exhibit different binding affinities for the 
neurotransmitter DA. The DA D5 receptor has 10 times greater binding affinity for DA 
than the DA D1 receptor (Grandy et al., 1991). To date, there is no selective agonist or 
antagonist that distinguishes between the D1 and D5 receptor subtypes. Activation of 
either the DA D1 or the DA D5 receptor leads to increased levels of AC, via activation of 
the G-protein. In fact, cells selectively expressing DA D5 receptors exhibit higher levels 
of AC basal activity than cells expressing DA D1 receptors (Tiberi and Caron, 1994). 
Adenylyl cyclase then activates cAMP, which can activate targets such as, kinases and 
phosphatases. These proteins, in turn, can activate (or inactivate) calcium and potassium 
ion channels or other cell surface receptors, thereby affecting the membrane potential of 
the cell and subsequent neurotransmitter release, such as ACh from cholinergic 
interneurons that highly express the DA D5 receptor. Repeated activation of these 
intracellular cascades can potentially lead to changes in neuroplasticity, such as long-term 
potentiation.  
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1.3.2 Dopamine D2 Receptor Subfamily 
Dopamine receptors classified in the D2 subfamily include the DA D2, D3 and 
D4 receptor subtypes. Unlike the DA D1 receptor family, activation of receptors in the 
DA D2 receptor subfamily leads to a decrease in AC and cAMP levels. Dopamine binds 
to the DA D3 receptor subtype with an affinity that is 20 times greater than its binding 
affinity to the DA D2 receptor subtype (Sokoloff et al., 1990), presumably due to the 
structural differences in their third intracellular loops (Robinson et al., 1994). The DA D4 
receptor, on the other hand, is most readily distinguished from the other D2 receptor 
subtypes by its high affinity for clozapine, a DA agonist (Van Tol et al., 1991). 
Dopamine D2 receptors, in particular, have been shown to act primarily as autoreceptors, 
localized on the presynaptic terminal, where they mediate DA release from dopaminergic 
nerve terminals. The cellular mechanism underlying DA D2 autoreceptor function is the 
ability of this receptor to induce the efflux of potassium from the cell. This outward 
potassium current leads to the hyperpolarization of the cell membrane, thereby inhibiting 
the release of DA from the axon terminal (Greif et al., 1995). A similar inhibitory 
mechanism on cell firing is postulated for cholinergic interneurons as well (Sil'kis, 2004). 
Furthermore, the DA D2 receptor subfamily has also been observed to mediate calcium 
currents, although the intracellular mechanisms are not completely understood. 
1.3.3 Dopamine Receptor Distribution in the Nucleus Accumbens 
Dopamine D1 and D2 receptors are the most predominant receptor subtypes in the 
striatum, including the NAcc (Gingrich and Caron, 1993). The MSNs in the NAcc 
express high levels of DA D1 and D2 receptors, although not likely expressed in equal 
proportion. In fact, there has been a long standing controversy over the expression of 
these two particular receptor subtypes on MSNs. These projection neurons have been 
divided into two distinct populations. One group of MSNs expresses high levels of DA 
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D1 receptors as well as substance P and projects primarily to the SN and internal segment 
of the globus pallidus (GPi). The second population of MSNs expresses high levels of 
DA D2 receptors and enkephalin and projects to the external segment of the globus 
pallidus (GPe) (Gerfen, 1992). Gerfen and colleagues continue to publish studies 
supporting the existence of these two pathways, which he refers to as the direct (D1-
mediated) and indirect (D2-mediated) striatal projection pathways (Gerfen, 2000, 2003, 
2006). Still, other studies report that MSNs projecting to the SN and GPi also send 
projections to the GPe, which suggests that these pathways are not discrete (Kawaguchi 
et al., 1990). Another line of evidence arguing against the separate MSN projection 
pathways is the subpopulation of MSNs (20-25%) that co-express D1 receptors, 
substance P, D2 receptors and enkephalin (Surmeier et al., 1996).  
The remaining DA receptor subtypes, are expressed at lower levels in the NAcc, 
with the exception of the DA D3 receptor, which is found at higher levels in the NAcc 
than in the dorsal striatum (Schwartz et al., 1998). The expression of the DA D3 receptor 
appears to be more highly concentrated in the NAcc, olfactory tubercle and the minor 
islands of Calleja (Bouthenet et al., 1991). The DA D5 receptor, which is reportedly 
expressed at low levels in the NAcc, is found at high concentrations on cholinergic 
interneurons (Bergson et al., 1995; Yan and Surmeier, 1997), with little to no expression 
of the D1 receptor subtype (Le Moine et al., 1990).  Finally, DA D4 receptors account for 
little of the DA D2-like binding in the NAcc (15%) or dorsal striatum (10%), as 
compared to other brain areas, such as the hippocampus (55%), dorsolateral (51%) 
medial prefrontal (47%) and entorhinal (42%) cortices (Tarazi et al., 1997). 
1.4 Immediate Early Gene Expression  
The IEG, c-fos, is activated quickly (~ 5minutes) following a stimulus, with 
protein levels peaking at about 2-3 hours and returning to baseline after 8 hours (Hope, 
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1998). The phosphoprotein product of the IEG c-fos, Fos, is located in the nucleus and 
can bind to other IEG proteins, such as Jun, forming the transcription factor AP-1 
complex (Hope, 1998). The AP-1 complex then regulates the transcription of genes 
downstream. These proteins are known to be involved in the early portion of the 
signaling cascades needed for cell growth and differentiation. The induction of Fos 
expression during the early stages of learning has been previously reported to correlate 
with sites of synaptic plasticity after repeated treatment (Kleim et al., 1996). Moreover, a 
separate class of Fos-like proteins called chronic Fos-related antigens (FRAs) is induced 
following chronic, but not acute, drug administration (Hope et al., 1994; Nye et al., 1995; 
Nye and Nestler, 1996). The chronic FRAs are more stable than the Fos-like proteins 
induced acutely, which are less stable and short-lived. Delta FosB is a splice variant of 
the IEG FosB and accumulates after chronic drug treatment in a region-specific manner 
(Nestler et al., 1999). Delta FosB binds with Jun proteins to form stable and long-lasting 
AP-1 complexes, which are believed to mediate some of the long-term effects of drug 
abuse and dependency (Nestler et al., 2001).   
1.5      Cocaine 
Cocaine, a psychostimulant, comes from the leaves of the coca plant. In 1855, 
Friedrich Gaedcke, a German chemist, was the first person to isolate the cocaine alkaloid, 
which he named erythroxyline and published in the journal Archives de Pharmacie. Four 
years later, Albert Niemann, a graduate student at the time, studied the coca leaves at the 
University of Gottingen in Germany, where he worked to improve the purification 
process of erythroxyline, giving it the name cocaine. He published his findings on the 
purification process of cocaine in his dissertation in 1860 (Wikpedia, 2006). In 1884, 
Sigmund Freud published On Coca, advocating the medicinal properties of cocaine and 
claiming that cocaine can be used to treat illnesses, including alcoholism and opioid 
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addiction (Koob and Le Moal, 2006). After watching a friend suffer from cocaine-
induced psychosis (characterized by hallucinations that white snakes were slithering over 
his body and that insects were crawling underneath his skin) in an attempt to use cocaine 
to alleviate nerve pain (Petersen, 1977), Freud recanted his previous statements on 
cocaine and published Craving for and Fear of Cocaine in 1884 (Koob and Le Moal, 
2006). 
Cocaine’s mechanism of action in the brain is to block monoamine transporters. It 
has a high affinity for the DA transporter (DAT) in particular, although it also binds to 
the norepinepherine and serotonin transporters, but with less potency. Cocaine binds to 
the DAT, blocking the ability of the transporter to remove excess DA from the synaptic 
cleft, resulting in elevated levels of extracellular DA. This increase in DA is responsible 
for the euphoric effects reported by cocaine users (Volkow et al., 1999). The excess DA 
can then bind to more available DA receptors, triggering intracellular cascades that lead 
to changes in cell firing rates and possible structural changes. Additionally, cocaine 
blocks sodium channels (Laposata, 1991), which allows the drug to further interfere with 
the propagation of action potentials.  
Cocaine is a stimulant that causes hyperactivity, increased blood pressure, heart 
rate, and euphoria. The half-life of cocaine is 40-50 minutes, with its euphoric effects 
peaking at about 15-20 minutes. Excessive doses of cocaine can cause hallucinations, 
paranoia, seizures, and heart-failure (Withers et al., 1995). 
1.5.1 Cocaine-Induced Dopamine, Acetylcholine, and Glutamate 
Neurotransmission in the Nucleus Accumbens 
Cocaine affects a number of major neurotransmitter systems in the brain, 
including, but not limited to, DA, ACh and glutamate. Cocaine increases DA levels in the 
brain by blocking DAT, which serves to re-uptake DA into the presynaptic terminal, 
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thereby leaving more available DA in the synaptic cleft. Dr. Volkow and colleagues have 
demonstrated, using positron emission tomography (PET), that at least 47% of DAT sites 
have to be blocked for human subjects to perceive the euphoric effects of cocaine 
(Volkow et al., 1997). Furthermore, a series of experiments have reported that animals 
lacking the gene for production of the DAT, called DAT knock out animals, do not 
exhibit enhanced locomotor activity (Giros et al., 1996), but continue to self-administer 
cocaine (Rocha et al., 1998) and exhibit conditioned place preference (Sora et al., 1998). 
This suggests that increased extracellular levels of DA are maintained in the NAcc 
following cocaine administration even in the absence of this particular monoamine 
transporter. Carboni et al., (2001) reported that DAT knock out animals did in fact 
undergo increases in DA levels in the medial NAcc, thereby supporting the role of the 
NAcc in cocaine reinforcement.  
Acetylcholine has been implicated in cognitive processes (Robbins et al., 1997), 
memory (Torres and Raz, 1994), and also drug abuse and dependency. Rats with an 
extensive cocaine drug history show enhanced ACh release in the NAcc during cocaine 
self-administration (Mark et al., 1999). Interestingly, inhibition of acetylcholinesterase 
(AChE), an enzyme that breaks down ACh, blocks the induction of cocaine-induced 
hyperactivity as well as prevents the behavioral expression of conditioned place 
preference in animals receiving repeated i.p. injections of cocaine or morphine (Hikida et 
al., 2003). These studies suggest that the route of administration and cues associated with 
drug delivery likely influence the release and overall function of ACh in the NAcc. 
Moreover, ACh receptors contribute to processes underlying reward and reinforcement. 
Specifically, muscarinic receptors, such as the m5 receptor expressed on neurons in the 
VTA, mediate hypothalamic brain stimulation (Yeomans et al., 2000); whereas 
inactivation of nicotinic receptors, with i.p. administered nicotinic antagonist 
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mecamylamine, decreases sensitivity to cocaine, evident by disruption of cocaine-
induced conditioned place preference (Zachariou et al., 2001). Moreover, both receptor 
types regulate DA release in the striatum (Zhou et al., 2001; Zhang et al., 2002). 
Blockade of nicotinic or muscarinic receptors reduces the potency of cocaine (Levin et 
al., 2000; Rasmussen et al., 2000). Finally, ablation of cholinergic neurons in the NAcc 
produces increased sensitivity to cocaine by inducing robust conditioned place preference 
to lower doses of cocaine (Hikida et al., 2001). Such evidence strongly suggests that ACh 
may also participate in cellular processes underlying cocaine abuse and dependency. 
Finally, cocaine increases glutamate release in the NAcc (Smith et al., 1995). A 
major neuroanatomical circuit recruiting the glutamatergic systems in drug reinforcement 
is the mesocortical dopaminergic pathway (Pierce and Kalivas, 1997). At the molecular 
level, cocaine increases DA levels within the PFC and NAcc, receiving dopaminergic 
input from the VTA (Tzschentke, 2001). Dopamine release in the prefrontal cortex can 
either activate (Nasif et al., 2005) or inhibit (Peterson et al., 1990) pyramidal neurons 
whose axon terminals innervate the NAcc. Dopamine D1 receptor activation on 
pyramidal neurons results in depolarization of these neurons and subsequent release of 
glutamate in the NAcc.  Pharmacological studies show that the glutamatergic increases in 
the NAcc are heavily dependent on dopaminergic systems. If DA terminals in the NAcc 
are destroyed or the chemical actions of DA are blocked, cocaine-stimulated glutamate 
release in the NAcc is also blocked (Reid et al., 1997). At the behavioral level, DA and 
glutamate release into the NAcc appear to correlate with the expression of behavioral 
sensitization (Reid and Berger, 1996). Moreover, if NMDA receptors are blocked in the 
VTA during pretreatment with cocaine, not only is the induction of behavioral 
sensitization blocked (Kalivas and Alesdatter, 1993), but also neuroadaptations 
associated with cocaine-induced sensitization, such as DA autoreceptor subsensitivity (Li 
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et al., 1999b). However, if animals are administered NMDA receptor antagonists after 
cocaine pretreatment, but before the challenge dose, behavioral sensitization is still 
observed (Li et al., 1999a). Therefore, NMDA receptors, although not necessary for the 
expression of cocaine-sensitization, may play a role in the induction of this drug-induced 
behavioral response.  
1.5.2 Cocaine-Induced Molecular Changes and Their Ability to Stimulate 
Morphological Changes in the Nucleus Accumbens 
The neuroadaptations that develop following cocaine administration occur at the 
molecular as well as the cellular level. At the molecular level, for example, repeated or 
persistent activation of intracellular cascades can lead to altered receptor sensitivity and 
synaptic plasticity, which can thereafter influence cellular responses to a repeated 
stimulus. In fact, a single injection of cocaine can induce long-term potentiation in VTA 
DA neurons (Borgland et al., 2004). Such molecular switches can cause 
neuroadaptations, not only in the electrophysiology of cells, but also in cellular 
morphology. For example, cocaine is reported to affect cytoskeletal proteins, such as 
Ankyrin (Hayashi and Su, 2001), a protein that modulates calcium efflux from the 
endoplasmic reticulum and Arc (Tan et al., 2000), a protein expressed in the dendrites of 
cells. Cytoskeletal proteins are important for cellular functions such as protein 
trafficking, dendritic growth and morphological maintenance of neurons. Thus, more 
recent drug studies have been aimed at looking for such morphological changes following 
long-term drug use. Increases in spine density on the dendrites of MSNs in the NAcc 
shell (Robinson and Kolb, 1999b) and core (Norrholm et al., 2003) are observed 
following long-term cocaine treatment; these spine changes appear to be at least in part 
dependent on the activity of cdk5, a protein that regulates the growth of neurites (Dhavan 
and Tsai, 2001). These studies demonstrate that cells will change their shape, as a result 
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of long-term treatment with cocaine. Such evidence further begs the question, are 
synaptic changes (i.e. changes in the physical connections between brain cells) also 
taking place? 
1.5.3 Cocaine-Induced Locomotor Behaviors and Stereotypies: Use in Studying 
Sensitization and Tolerance 
Cocaine induces a wide range of behaviors in rats, such as hyperlocomotion, 
excessive exploratory behavior, focused sniffing, headbobbing, as well as other repetitive 
purposeless behaviors. These repetitive behaviors are called stereotypies (Randrup and 
Munkvad, 1969), and become more pronounced with long-term drug treatment or with 
the administration of high drug doses. Drug-induced behaviors change over the course of 
drug treatment, when rats are given the same drug dose repeatedly over time. Initially rats 
exhibit hyperlocomotion following cocaine administration, but over time, rats start to 
spend less time exploring their environment and more time engaged in repetitive, 
seemingly purposeless behaviors, such as headbobbing and sniffing intensely in one 
location (Lyon and Robbins, 1975).  
Both hyperlocomotion and stereotypies are used to measure persistent behavioral 
changes as a result of drug treatment. One well-known drug-induced behavior is 
sensitization. Sensitization is defined as a physiological state characterized by an 
augmented effect of the drug that occurs following repeated administration of the same 
drug dose (Kalivas and Duffy, 1990; Robinson and Berridge, 1993). Behavioral 
sensitization is observed in rats following a single cocaine injection (Guan et al., 1985). 
Furthermore, the expression of cocaine-induced behavioral sensitization has been linked 
with increases in Fos expression in the NAcc shell and core (Crombag et al., 2002) as 
well as an increase in spine density on MSNs, specifically in the NAcc core (Li et al., 
2004). Additionally, stereotyped motor behaviors are induced by stimulation of DA 
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release in the striatum (Fog, 1972) and are abolished by destruction of DA terminals 
within the striatum (Fibiger et al., 1973). Moreover, these particular behaviors are 
strongly correlated with Fos activation in the striosomal compartments of the dorsal 
striatum in the rat (Canales and Graybiel, 2000) and appear to be dependent on the co-
activation of D1 and D2 receptors (Capper-Loup et al., 2002), presumably because of 
their synergistic properties upon concurrent activation. Glutamatergic systems are also 
implicated in the modulation of cocaine sensitization. Whether glutamatergic systems 
mediate the development or expression of stereotypic behaviors remains to be 
determined. At present, DA mechanisms alone do not fully explain the locomotor or 
stereotypic behaviors that emerge with repeated drug administration (Rebec, 2006). 
Despite evidence that cocaine does not directly activate glutamate receptors, pretreatment 
with NMDA or AMPA receptor antagonists prevents the induction of locomotor 
sensitization to cocaine in drug-naïve animals. Repeated stimulation of the PFC leads to 
the expression of sensitization (Schenk and Snow, 1994), whereas lesions to the PFC 
block the development of sensitization (Tzschentke and Schmidt, 1998).  
Lastly, behavioral tolerance depends on dose, duration, and frequency of 
administration. Tolerance to cocaine is believed to be one of the reasons behind dose 
escalation in chronic users. Cocaine tolerance does not appear to be due to changes in 
drug metabolism (Inada et al., 1992; Katz et al., 1993) or a change in cocaine levels in the 
brain (i.e. pharmacokinetic tolerance) following repeated treatment with cocaine (Reith et 
al., 1987). Supersensitivity of DA D2 autoreceptors is believed to regulate tolerance to 
cocaine (Ellinwood et al., 2000). In rats receiving cocaine continuously, cocaine-induced 
locomotor activity can be used to measure motor tolerance (King et al., 1999), yet 
recovery of weight loss as a result of cocaine treatment is another reported measure for 
tolerance (Epstein and Altshuler, 1978). To date, cocaine-induced tolerance in rats has 
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not been correlated with a reduction in the expression of stereotyped behaviors following 
repeated drug administration. However, stereotyped headbobbing has been correlated 
with tolerance in rabbits when cocaine is administered prenatally (Simansky and 
Kachelries, 1996; Stanwood and Levitt, 2003). Stereotyped headbobbing to 
psychostimulants administration is more pronounced in rabbits; thus, perhaps studies 
comparing neurochemical changes in rats and rabbits exhibiting tolerance to cocaine can 
help identify specific neuronal substrates underlying this behavioral adaptation.  
1.6 Morphine 
Morphine is a natural alkaloid of opium, which comes from the milky juice of the 
unripe seed of the opium poppy. This alkaloid was named after the Greek god of dreams, 
Morpheus (van Ree et al., 1999). This chemical binds to endogenous opioid receptors (µ, 
κ and δ) in the brain, and mice will self-administer morphine directly into the NAcc 
(Olds, 1982).  In fact, mice, if given a choice between the amygdala and VTA, will 
preferentially self-administer morphine into the VTA (David and Cazala, 1994).  
Moreover, repeated infusions of morphine into the VTA do not result in the behavioral 
expression of physical dependence (Bozarth and Wise, 1984). Therefore, morphine’s 
molecular actions in the VTA may be more involved in the rewarding and reinforcing 
properties of the drug.  
Morphine’s mechanism of action on the mesolimbic DA pathway involves 
binding to µ- and δ-opioid receptors expressed by GABAergic (inhibitory) interneurons 
in the VTA. Activation of this receptor results in hyperpolarization (inhibition of cell 
firing) of GABA interneurons, thereby activating DA neurons through disinhibition 
(Gysling and Wang, 1983; Johnson and North, 1992). These molecular events lead to the 
release of DA in the NAcc, PFC, as well as other limbic-associated brain areas. 
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Morphine is used medically as an analgesic. However, tolerance quickly 
develops, requiring higher doses of the drug to control pain. Side effects of long-term 
opioid use include insomnia, calmness and euphoria followed by dysphoria, increased 
anxiety, irritability and depression (Barbour and Lilly, 1976; Staedt et al., 1996) as well 
as a high potential for addiction. Morphine-dependent individuals and animals exhibit 
physical withdrawal symptoms when drug administration ceases (Himmelsbach, 1942). 
Tolerance to morphine (or other opioid-derived drugs) increases the likelihood of a drug 
overdose, which can lead to a comatose state or accidental death (Ellenhorn and 
Barceloux, 1988).    
1.6.1 Morphine-Induced Dopamine, Acetylcholine, and Glutamate 
Neurotransmission in the Nucleus Accumbens 
As previously mentioned, morphine acts on µ- and δ-opioid receptors to indirectly 
activate DA neurons in the VTA thereby increasing DA release in limbic-related target 
structures, namely the NAcc. Activation of µ-opioid receptors in the VTA increases DA 
neurotransmission in the NAcc (Spanagel et al., 1992), whereas activation of κ-opioid 
receptors decreases accumbal DA release (Di Chiara and Imperato, 1988). Additionally, 
if morphine is administered directly into the NAcc, the mechanism underlying enhanced 
DA release appears to be dependent upon the activation of δ-opioid receptors, as opposed 
to µ-opioid receptors (Borg and Taylor, 1997). Interestingly, robust conditioned place 
preference is observed in mice that are unable to synthesize DA, thus demonstrating that 
DA is not required to induce morphine conditioned place preference. Moreover, these 
animals exhibit a small DA-independent increase in locomotion following morphine 
administration (Hnasko et al., 2005). Dopamine increases in the NAcc of morphine-
sensitized rats are regionally specific. The core compartment of the NAcc shows 
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increases in DA, while the shell shows decreases relative to control rats (Cadoni and Di 
Chiara, 1999).  
Acetylcholine release in the NAcc has also been reported following the 
administration of morphine. Acetylcholine levels in the NAcc core and shell decrease 
following acute morphine administration, but increase after chronic treatment with 
morphine (Fiserova et al., 1999). The long-lasting changes in accumbal ACh release 
appear to be regulated by δ-opioid receptors (Tjon et al., 1995).  Destruction of ACh-
containing neurons in the NAcc results in enhanced sensitivity to morphine’s rewarding 
effects, measured using conditioned place preference; however, in the same study, 
conditioned place aversion was also increased in these animals during morphine 
withdrawal (Hikida et al., 2003). In addition, when the metabolism of ACh is blocked, 
using AChE inhibitors, morphine conditioned place preference is also blocked (Hikida et 
al., 2003). 
The administration of opioids inhibits glutamate release in the NAcc (Sepulveda 
et al., 1998). Withdrawal from morphine, on the other hand, coincides with an increase in 
glutamate release in the NAcc (Sepulveda et al., 2004). A more recent study reported a 
similar increase in glutamate neurotransmission, specifically in the NAcc core, 3 weeks 
after a single morphine injection (Jacobs et al., 2005). Glutamatergic mechanisms are 
also thought to mediate behavioral sensitization to morphine. For example, the induction 
of behavioral motor sensitization is prevented when NMDA or AMPA receptor 
antagonists are co-administered with morphine (Wolf and Jeziorski, 1993; Jeziorski et al., 
1994; Carlezon et al., 1999).  
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1.6.2 Morphine-Induced Molecular Changes and Their Ability to Stimulate 
Morphological Changes in the Nucleus Accumbens  
Neuroadaptations resulting from chronic opioid administration have been the 
focus of many recent studies. The NAcc shell and core of morphine-sensitized rats are 
more metabolically active than drug-naïve animals (Kraus and Kornetsky, 2000). Long-
term treatment with morphine, followed by a 1 month withdrawal period, results in a 
significant decrease in the number of dendritic branches and  spine density of MSNs in 
the NAcc shell (Robinson and Kolb, 1999a; Robinson et al., 2002). One possible 
mechanism underlying these observed changes in spine density is the ability of µ-opioid 
receptors to regulate stability of dendritic spines (Liao et al., 2005). Thus, while δ-opioid 
receptors play more of a role in DA neuron stimulation in the VTA, the µ-opioid 
receptors potentially affect the integration of glutamatergic and dopaminergic signals, 
which reportedly converge onto dendritic spines, in the NAcc. The functional relevance 
of these morphological changes at the behavioral level is still unclear. Recently, cdk5, 
one of the proteins reportedly responsible for the dendritic spine proliferation resulting 
from chronic cocaine treatment, has also been implicated as a key molecular substrate 
involved in the mechanisms underlying morphine-induced behavioral sensitization in 
mice (Narita et al., 2005) and antinociceptive tolerance in rats (Wang et al., 2004). 
1.6.3 Morphine-Induced Locomotor Behaviors and Stereotypies: Use in Studying 
Sensitization and Tolerance 
The behavioral effects observed following acute and chronic morphine 
administration are described as biphasic, and contrast sharply with those induced by 
psychostimulants. Low doses of morphine administered to drug-naïve animals produce an 
inhibitory effect on locomotor activity, called opiate catalepsy (Muley et al., 1982), an 
effect that can be induced by intracranial infusions of morphine (5-15 µg) directly into 
the NAcc (Winkler et al., 1982). Moreover, high doses of morphine also produce 
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hyperlocomotion (Narita et al., 1993; Manzanedo et al., 1999). Dosing and frequency of 
drug administration, among other variables, greatly impact the expression of drug-
induced behaviors. Morphine-induced hyperactivity is regulated to some degree by the 
actions of DA via the mesolimbic DA pathway. In fact, the VTA, and not the NAcc, 
appears to be responsible for the hyperactivity observed in morphine-sensitized animals 
(Kalivas and Duffy, 1987; Vezina et al., 1987). Despite this overlap in neurocircuitry 
between morphine and psychostimulants (i.e. activation of the mesolimbic DA pathway), 
morphine-induced hyperactivity is behaviorally different than the hyperlocomotor 
response to cocaine. First, morphine-induced hyperactivity is limited to increases in 
lateral activity and sniffing behavior, none of which is correlated with an increase in 
rearing activity (Laviola et al., 1994; Kuzmin et al., 2000).  Second, unlike cocaine-
induced hyperlocomotion, DA receptors do not appear to play a major role in mediating 
opioid sensitization (Kalivas et al., 1985; Jeziorski and White, 1995). Thus the cellular 
mechanisms underlying morphine sensitization require further examination. Cross-
sensitization studies will likely prove useful tools for differentiating the mechanisms 
underlying such persistent behavioral adaptations. 
Stereotyped behaviors due to chronic morphine treatment include excessive 
chewing/gnawing (Pollock and Kornetsky, 1989) and licking (Cadoni and Di Chiara, 
1999). The shell and core compartments of the NAcc show enhanced metabolic activity 
in morphine-sensitized animals exhibiting this oral stereotypy (Kraus and Kornetsky, 
2000). The precise neuronal mechanism responsible for this behavior is poorly 
understood. Fluoxetine (a serotonin reuptake inhibitor), MK-801 (NMDA receptor 
antagonist), and SCH23390 (DA D1 receptor antagonist) all block the expression of this 
morphine-induced oral stereotypy; however, only the NMDA receptor antagonist 
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partially prevented the development of sensitization (Livezey et al., 1995; Wennemer and 
Kornetsky, 1999).  
Morphine-induced locomotor activity as well as stereotyped chewing/gnawing has 
been used to measure opioid-induced sensitization, while tolerance to morphine is 
typically measured by its reduced analgesic effects over time. Tolerance occurs quickly 
and is more widely reported in morphine-related studies, as compared to studies 
involving psychostimulants. Opioid tolerance to pain is typically measured using the tail 
flick response (Grumbach and Chernov, 1965), which measures the diminishing analgesic 
effects of morphine during the course of repeated administration (Patrick et al., 1978; 
Siegel et al., 1981). Less well-known, and less well-studied, is opioid catalepsy (De Ryck 
et al., 1980; De Ryck and Teitelbaum, 1984; Fischer et al., 2002) as a measure of motor 
tolerance in the rat (Walter and Kuschinsky, 1989).     
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Chapter 2: Cholinergic Interneurons of the Nucleus Accumbens and 
Dorsal Striatum are Activated by the Self-Administration of Cocaine 
2.1 Abstract 
The nucleus accumbens, a major component of the ventral striatum, and the dorsal 
striatum are primary targets of the mesolimbic dopamine pathway, which is a pathway 
that plays a critical role in reward and addiction. The shell compartment of the nucleus 
accumbens and the ventromedial striatum, in particular, receive extensive afferent 
projections from the ventral tegmental area, which is the major afferent source of the 
mesolimbic pathway (Gerfen et al., 1987; Amalric and Koob, 1993). The present study 
tested the hypothesis that striatal cholinergic interneurons of the nucleus accumbens are 
activated by the acute self-administration of cocaine. The main finding of this study is 
that cholinergic interneurons located in the dorsal medial shell compartment of the 
nucleus accumbens and the ventromedial striatum were activated, as measured by Fos 
labeling, following a 1 h session of the self-administration of cocaine in rats. A direct 
positive correlation existed between the percent of cholinergic interneurons that were 
activated and the amount of cocaine that was self-administered. The greatest amount of 
administered cocaine (approximately 10 mg/kg) resulted in the activation of 
approximately 80% of the cholinergic neurons. No such correlation existed in the group 
of animals that self-administered saline. In addition, activation was not found in the core 
compartment of the nucleus accumbens or the dorsolateral striatum, which receive 
extensive innervation from the substantia nigra and thus are more closely tied to the 
motor effects of the drug. In conclusion, cocaine-driven neuronal activation was specific 
to the shell compartment of the nucleus accumbens (R2=0.9365) and the ventromedial 
striatum (R2=0.9059). These findings demonstrate that cholinergic interneurons are 
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involved in the initial stage of cocaine intake and that these neurons are located in areas 
of the nucleus accumbens and dorsal striatum that are more closely tied to the rewarding 
and hedonic effects rather than the motor effects of cocaine intake. 
2.2 Introduction 
The nucleus accumbens (NAcc) and the dorsal striatum have traditionally been 
regarded as an interface between limbic and motor systems. These areas of the brain 
receive extensive dopaminergic innervation from the ventral tegmental area (VTA) and 
the substantia nigra (SN), which subserve primarily limbic and motor function, 
respectively. The mesolimbic DA pathway originating in the VTA, which is targeted by 
several drugs of abuse including cocaine, amphetamine, heroin, morphine, nicotine, and 
alcohol (Self and Nestler, 1995; Berke and Hyman, 2000; Koob and Le Moal, 2001; 
Nestler, 2001), extensively innervates the shell compartment of the NAcc and the 
ventromedial striatum (Gerfen et al., 1987; Amalric and Koob, 1993). The SN, which is 
primarily involved in motor function, instead primarily innervates the core region of the 
NAcc (Nirenberg et al., 1996) and the dorsolateral striatum (Gerfen and Sawchenko, 
1984). In order to understand the behavioral correlates and cellular adaptations that 
accompany addiction, it is essential to examine these striatal pathways both at the global 
systems level as well as at the cellular level. The neostriatum, therefore, should be 
examined in terms of its functionally distinct components, at the level of individual 
neurons and related microcircuitry, in order to fully understand the cellular and 
behavioral mechanisms that underlie drug abuse and addiction.  
The focus of the present study was on a specific cell type, striatal cholinergic 
interneurons, which are important neuronal integrators and modulators of striatal function 
and dysfunction. These neurons possess receptors that are linked to molecular signaling 
pathways, which are critical for plasticity (Calabresi et al., 1999), long-term potentiation 
(LTP) (Suzuki et al., 2001), and associative learning (Aosaki et al., 1994). Cholinergic 
interneurons in turn exert powerful influences on medium spiny output neurons (MSNs) 
and thus on overall striatal signaling (Howe and Surmeier, 1995). Cholinergic 
neuromodulation specifically facilitates LTP expression in MSNs as well as N-methyl- -
aspartate (NMDA) receptor-mediated corticostriatal signaling onto MSNs (Calabresi et 
al., 1992; Calabresi et al., 2000). Accumulating evidence from pharmacological and 
behavioral studies further suggests a central role for cholinergic neurons in mediating 
addiction-related behaviors. Pharmacological evidence, for example, has shown that 
acetylcholine (ACh) levels increase in the NAcc following the administration of cocaine 
in the rat (Consolo et al., 1999; Mark et al., 1999).  
The present study tested the hypothesis that cholinergic interneurons in specific 
areas of the NAcc (shell) and the dorsal striatum (ventromedial striatum), which are 
targeted by the mesolimbic DA pathway, are activated by the self-administration of 
cocaine. Together, the findings implicate cholinergic interneurons in these areas of the 
neostriatum in addictive processes. (This study has been published: Berlanga et al., 
2003). 
2.3 Methods 
Each experimental group (Acute or Chronic) was divided further into those 
receiving cocaine or saline. Animals were allowed to self-administer during a single 1-h 
session (Acute group) or for daily 1-h sessions across a 2-week period (Chronic group). 





Thirty-two male Sprague–Dawley rats were obtained from the Animal Resource 
Center at the University of Texas at Austin. All experimental procedures conformed to 
National Institutes of Health guidelines and were carried out under an institutionally 
reviewed and approved research protocol. Animals were group housed and handled for 2 
weeks, and then trained to lever press for sugar pellets on a fixed ratio 1 (FR1) schedule 
for 1 week before receiving surgery. All efforts were made to minimize animal suffering 
and the number of animals used. 
2.3.2 Surgical Procedures 
Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and 
supplemented with chloral hydrate (80 mg/kg, i.p.) as needed. Atropine sulfate 
(350 µg/animal) was administered prophylactically to alleviate potential respiratory 
congestion. A silastic catheter (0.625 mm, o.d.) was inserted into the right external 
jugular vein. The free end of the catheter, fused with a modified cannula termination 
(C313G; Plastics One, Roanoke, VA, USA), was run subcutaneously along the side of the 
neck and out an incision in the skin at the top of the skull. The cannula termination was 
embedded into dental acrylic and secured to the skull with four stainless steel screws. 
Intravenous catheter patency was maintained as previously described (Emmett-Oglesby 
et al., 1993). 
2.3.3 Self-Administration 
Self-administration procedures were conducted as previously described (Ikegami 
et al., 2002). Briefly, self-administration sessions were 1 h in duration. Saline and cocaine 
injections were infused according to an FR1 schedule followed by a 20-s timeout. Each 
lever press resulted in an infusion of 0.75 mg/kg or an equal volume of saline and 
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illumination of a stimulus light. Locomotor activity was assessed by photobeam breakage 
at three locations along the length of the operant chambers. Experimental programs were 
run and data were acquired using an IBM compatible computer using MED-PC software 
(MED Assoc., St. Albans, VT, USA). 
2.3.4 Tissue Preparation 
Animals were anesthetized deeply with sodium pentobarbital and perfused 
transcardially with 50 ml of 0.1 M phosphate-buffered saline (PBS) followed by 200 ml 
of 4% paraformaldehyde/0.1% glutaraldehyde (pH 7.4). Brains were removed and post-
fixed for 2 h. Vibratome sections (100 µm thick) were collected into 0.1 M PBS, and 
frozen in liquid nitrogen and stored at −80 °C until they were processed for 
immunocytochemical labeling. 
2.3.5 Dual Immunocytochemistry 
Free-floating sections were washed in 0.1 M PBS and washed again in PBS 
following each of the subsequent steps. Sections were incubated in 5% normal goat 
serum (NGS)/1% H2O2 in PBS for 1 h. Sections were then incubated in a cocktail of 
primary antibodies for choline acetyl-transferase (ChAT; monoclonal, 1:1000; Chemicon, 
Temecula, CA, USA) and c-Fos (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) in 5% NGS overnight at 4 °C. The tissue was then incubated in secondary 
biotinylated donkey anti-mouse IgG antiserum (1:500; Jackson ImmunoResearch, West 
Grove, PA, USA), diluted in 2% NGS-PBS for 2 h, and then incubated in an avidin–
biotin peroxidase complex (ABC; Vectastain Elite Kit; Vector, Burlingame, CA, USA) 
for 1 h. ChAT-immunoreactivity (IR) was visualized with 0.05% 3,3′-diaminobenzidine 
tetrahydrochloride (DAB) and 0.01% H2O2 in PBS which resulted in a brown reaction 
product. The sections were then incubated for 1 h in biotinylated donkey anti-rabbit IgG 
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(1:200; Chemicon, Temecula, CA, USA) followed by incubation in ABC for 1 h. Fos-IR 
was then visualized with a Vector SG (blue) label. 
2.3.6 Quantitative Analysis 
Three digital images representing areas of 0.45 mm2 for each hemisphere along 
the dorso-ventral extent of the medial NAcc shell and core, and one digital image 
representing an area of 0.45 mm2 for each hemisphere in the ventromedial and 
dorsolateral striatum were acquired from tissue from each animal using a 10× objective 
on a Nikon Eclipse E800 light microscope. Images were stored and analyzed by two 
observers blind to group assignment. The observers counted all cholinergic cells in the 
0.45 mm2 sample area (as determined by brown DAB label) and determined the percent 
of cholinergic cells that co-expressed Fos as indicated by the blue SG label. The total 
percent of Fos-labeled cholinergic neurons per animal was calculated as an average of the 
total sampled areas. The areas sampled were taken from the medial quadrant of the shell 
compartment of the NAcc and the ventromedial striatum (1.60 mm Bregma (Paxinos and 
Watson, 1998)), which is an area that receives heavy dopaminergic innervation from the 
VTA. In addition, samples were also taken from two areas associated with motor 
function, the core compartment of the NAcc and the dorsolateral striatum. These two 
areas receive their dopaminergic innervation primarily from the SN. 
2.4 Results 
Cholinergic interneurons of the dorsal and ventral striatum of the rat were 
identified using immunocytochemistry procedures and an antibody against ChAT. Fig. 
2.1A illustrates ChAT-immunolabeled neurons of the striatum. Cholinergic cells that 
were activated were determined by dual immunolabeling for ChAT and Fos protein. A 
representative photomicrograph of Fos-labeled cholinergic cells is shown in Fig. 2.1B. 
The percent of neurons activated were calculated from samples taken from specific 
regions of the dorsal and ventral striatum (1.60 mm Bregma(Paxinos and Watson, 1998)) 




Figure 2.1 Fos immunoreactive cholinergic interneurons. Cholinergic interneurons 
expressing Fos located in the striatum of the rat brain were identified by 
immunocytochemical dual labeling procedures using an anti-ChAT antibody and DAB 
label (brown) and an anti-Fos antibody and SG label (blue). (A) An image illustrating 
cholinergic interneurons identified by ChAT immunolabeling. Cholinergic cell somata 
measured 30–50 µm in diameter and their neuronal processes measured up to a millimeter 
in length. The neurons were frequently situated in neuronal clusters. (B) Tissue dual 
labeled for ChAT and Fos identified cholinergic interneurons (brown) and cholinergic 






Figure 2.2 Nucleus accumbens and striatum atlas plate used for quantification. A 
Coronal section of the rat brain at Bregma 1.60 mm (Paxinos and Watson, 1998) showing 
regions of the NAcc and dorsal striatum where photomicrographs were taken and used 
for quantification procedures (represented by black and gray boxes). Cholinergic 
interneurons in the shell compartment of the NAcc and the ventromedial striatum are 
areas that are innervated by the VTA (represented by black boxes). These areas revealed 
a direct correlation between Fos expression and the self-administration of cocaine. 
However, cholinergic cells in areas innervated by the SN, namely the core compartment 
of the NAcc and the dorsolateral striatum (represented by gray boxes) did not show a 
direct correlation between Fos expression and the self-administration of cocaine. 
 
The amount of cholinergic neuronal activation that occurred, as measured by Fos 
labeling, was strongly correlated with the amount of cocaine that was self-administered. 
In other words, a greater percentage of activated cholinergic neurons located in the shell 
compartment of the NAcc and the ventromedial striatum occurred with increased levels 
of the self-administration of cocaine compared with the self-administration of saline. The 
greatest amount of cocaine that was self-administered (approximately 10 mg/kg) resulted 
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in the activation of 84% of the cells in the shell compartment of the NAcc and 79% of the 
cells in the ventromedial striatum. No such correlation existed in the group of animals 
that self-administered saline. Cocaine-driven neuronal activation was specific to the shell 
compartment of the NAcc (R2=0.9365) and the ventromedial striatum (R2=0.9059). 
Neuronal activation in these areas did not increase with increased levels of saline 
administration in either the NAcc (R2=0.2307) or the ventromedial striatum (R2=6E-05). 
Furthermore, activation was not found in the motor-associated core compartment of the 
NAcc in the cocaine (R2=0.0413) or saline (R2=0.0961) group or in the dorsolateral 
striatum in the cocaine (R2=0.0772) or saline group (R2=0.2456; Fig. 2.3). In addition, 
cholinergic activation did not appear to be due to motor activity, since neuronal activation 
was not correlated with the amount of bar pressing that occurred in the saline group (data 
not shown). Therefore, the greatest amount of cholinergic neuronal activation was not 
associated with saline administration or with motor activity per se. Instead, neuronal 




Figure 2.3 Percent of Fos immunoreactive cholinergic cells following cocaine 
self-administration. The percent of cholinergic cells that were activated, as 
measured by Fos, in the NAcc or dorsal striatum, plotted against the number of 
lever presses performed by a rat in a 1-h session of the self-administration of 
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cocaine or saline. Each lever press resulted in an infusion of 0.75 mg/kg of 
cocaine or saline. A direct correlation existed between the percent of Fos-IR 
(activated) cholinergic interneurons and the amount of self-administered cocaine 
in the shell compartment of the NAcc (R2=0.9365) and the ventromedial striatum 
(R2=0.9059), which are areas that receive VTA innervation. No correlation 
existed for the self-administration of saline in either the NAcc (R2=0.2307) or the 
ventromedial striatum (R2=6E-05). The amount of activated cholinergic neurons 
and the amount of self-administered cocaine or saline was not correlated in the 
motor areas of the NAcc, which are targeted by the SN. Specifically, the core 
compartment of the NAcc (cocaine: R2=0.0413, saline: R2=0.0961) and the 
dorsolateral striatum (cocaine: R2=0.0772, saline: R2=0.2456). 
2.5 Discussion 
The main finding of this study is that the cholinergic interneurons of the NAcc 
and dorsal striatum were activated in a dose dependent manner following a 1 h session of 
the self-administration of cocaine in rats. Specifically, the neurons activated were 
cholinergic interneurons located in the shell compartment of the NAcc and the 
ventromedial striatum. These brain areas receive direct innervation from the 
dopaminergic mesolimbic pathway, which plays an important role in reward and 
addiction (Self and Nestler, 1995).  
Cholinergic interneurons of the striatum possess a number of behavior-related, 
cellular, and molecular characteristics that position them as likely candidates important 
for mediating reinforcement and addiction-related phenomena. Specifically, cholinergic 
interneurons of the striatum integrate a variety of cognitive, limbic, and motor 
information (Calabresi et al., 2000). These neurons further undergo plasticity and 
learning and in turn influence striatal output signaling (Aosaki et al., 1994). The 
activation of these cholinergic neurons in the shell NAcc and ventral striatum following 
the first administration of cocaine suggests that these neurons play a role in the initial 
stage of drug intake and possibly in the learning mechanisms involved in the first 
exposure to the drug. The fact that the activation of these neurons was not correlated with 
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cocaine intake in the motor-associated core NAcc and dorsolateral striatum is consistent 
with pharmacological data that reports a dissociation between locomotor behavior and 
striatal ACh release (Zocchi and Pert, 1994). In the present study, we have identified a 
potential neuronal cell type and related microcircuitry, i.e. the cholinergic neuronal 
network system that may be critical for the initiation and maintenance of drug 
reinforcement and addiction. Fig. 2.4 illustrates the key cellular and molecular 
characteristics of cholinergic interneurons and their positioning within a more global 
systems level, which, overall, may play an important role in reinforcement and addiction-





Figure 2.4 Schematic of the cholinergic microcircuitry of the nucleus accumbens. 
This schematic depicts the cholinergic neuronal network system of the NAcc, in 
particular the microcircuitry involving dopamine (DA) and glutamate (GLU) afferent 
connections and receptors. The cholinergic neuronal network system receives and 
integrates important cortical and subcortical information and in turn provides a powerful 
influence on MSNs and thus on overall striatal signaling. The DA–GLU convergence 
onto these cholinergic neurons may provide a neural substrate by which the DA-mediated 
rewarding or hedonic effects of drugs are associated with such GLU-mediated 
information as contextual or motivational stimuli. These neurons, therefore, may play an 
important role in the cellular mechanisms that underlie learning and addiction. Overall, 
cholinergic neurons are posited to play an important role in (1) the establishment and 
maintenance of drug addiction via influences onto MSNs and (2) the modulation of 
incoming prefronto-striatal signaling. The PFC has the capacity to drive drug-seeking 
behaviors and relapse; however, it may also serve to inhibit striatal circuits that drive 
compulsive drug-seeking behaviors. Thus, cholinergic interneurons are an important 
component of the cellular and behavioral mechanisms that may drive addiction, but may 




Cholinergic involvement in drug addiction 
Increasing evidence from behavioral and pharmacological studies has 
convincingly demonstrated the importance of ACh in drug addiction. Pharmacological 
evidence, for example, has shown that ACh levels increase in the NAcc following the 
acute administration of cocaine (Consolo et al., 1999) and following chronic self-
administration of cocaine in rats (Mark et al., 1999). Such cocaine-induced striatal in vivo 
ACh release is regulated by dopamine (DA) D5 receptors (Consolo et al., 1992), which 
we have recently localized on cholinergic neurons (Berlanga et al., 2005). In accordance 
with these findings, we have provided compelling evidence in this paper that cholinergic 
interneurons of specific regions of the NAcc and dorsal striatum, as demonstrated by Fos 
labeling, are indeed activated following a 1 h session of the self-administration of cocaine 
in rats. It has been suggested that transient immediate early gene protein expression in 
neurons may trigger a cascade of cellular events that underlies long-term information 
storage, which is modified over time by a myriad of significant behavioral and cognitive 
stimuli (Clayton, 2000). It is possible, therefore, that although Fos labeling is a transient 
neuronal marker, that Fos expression may trigger neuroadaptive changes in receptor 
expression or long-term changes in synaptic wiring in cholinergic neuronal network 
systems in chronic and withdrawal conditions, which are questions that are currently 
under investigation in our laboratory.  
Pharmacological evidence supports the importance of ACh addiction-related 
phenomena. Systemic application of ACh muscarinic receptor blockers prevents the 
induction of behavioral sensitization to cocaine (Heidbreder and Shippenberg, 1996; 
Karler et al., 1996), suggesting a role for ACh in behavioral sensitization. Withdrawal 
from a sensitizing regimen of cocaine, on the other hand, produces transient, but dramatic 
up-regulation of both muscarinic M2 and dopamine D2 receptors (Sousa et al., 1999), 
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which in turn attenuate the response of ACh release (Calabresi et al., 1999). Interestingly, 
cocaine has relatively high affinity for the muscarinic M2 receptor, as well as the DA 
transporter (Sharkey et al., 1988). Given the discrete segregation of muscarinic M2 
receptor subtypes (Alcantara et al., 2001), as well as the presence of DA D2 receptors on 
cholinergic interneurons (Alcantara et al., 2003), it is highly probable that cholinergic 
interneurons of the NAcc play an important role in the neuroadaptations that accompany 
not only drug intake, but also withdrawal. Following this study, an analysis of DA D2 
and D5 receptor neuroadaptations, associated with cholinergic neuronal populations in 
the NAcc shell and core, was completed using a subsequent self-administration paradigm 
involving two drug conditions, chronic (2 weeks) cocaine and withdrawal (2 weeks 
cocaine followed by two weeks of abstinence). However, due to the low amounts of 
cocaine that were self-administered by the animals used in the study, the results were 
inconclusive. Additionally, drugs that enhance cholinergic neurotransmission in the 
medial prefrontal cortex, an area known to modulate mesoaccumbens DA transmission 
(Olsen and Duvauchelle, 2001), also increase instrumental responding for cocaine 
(Ikemoto and Goeders, 2000). Alternatively, lesions of the prefrontal cortex prevent 
induction of cocaine sensitization (Pierce et al., 1998; Li et al., 1999a). Specific lesions of 
cholinergic neurons in the nucleus basalis magnocellularis, a target of NAcc innervation, 
also attenuate the self-administration of cocaine (Robledo et al., 1998).  
 
Cholinergic neurotransmission may serve both to facilitate and attenuate addiction-
related phenomena 
The specific role that striatal cholinergic interneurons play in drug reinforcement 
and addiction will likely depend on their positioning within specific neuronal pathways 
and microcircuits. At the microcircuit level, ACh release will affect a variety of 
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muscarinic and nicotinic receptor subtypes, which evoke unique intracellular signaling 
mechanisms and physiological effects. At the systems level, cholinergic function will 
depend on the positioning of these cells within functionally distinct striosomal or matrix 
compartments and the direct or indirect striatal output pathways. The cholinergic–
cholinergic synaptic connections as well as the large size of cholinergic neurons and their 
extensive dendritic and axonal arborizations, in particular, may serve to provide a 
powerful cholinergic neuronal network influence over striatal functioning. The 
afferent/efferent connections of the cholinergic neurons will also dictate overall ACh 
function. In addition to the dopaminergic mesolimbic innervation, which has been 
implicated in incentive and habit learning (Di Chiara, 1998), the NAcc and dorsal 
striatum are also innervated by glutamatergic cortical and limbic afferents. Such 
dopamine–glutamate convergent influences onto cholinergic neurons may be especially 
important for mediating associative learning, which is an important process underlying 
addiction (Di Chiara, 1999; Vanderschuren and Kalivas, 2000).  
Associative learning has been reported to underlie context-specific psychomotor 
sensitization (Anagnostaras et al., 2002), which involves alterations in dopaminergic and 
glutamatergic neurotransmission (Vanderschuren and Kalivas, 2000) and may be linked 
to addiction. Such associative learning may likely involve the convergence of reward-
mediated mesolimbic dopaminergic afferents with hippocampal glutamatergic afferents 
onto MSNs of the NAcc. The MSNs have previously been reported to demonstrate 
altered plasticity in response to cocaine or amphetamine (Robinson and Kolb, 1999b; 
Robinson et al., 2001). It will be critical to examine whether such mesolimbic and 
hippocampal convergence exists onto MSNs, but more importantly, whether such 
convergence and altered synaptic plasticity occurs within cholinergic microcircuits. 
Specifically, the cholinergic interneurons of the medial shell compartment of the NAcc 
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and the ventromedial striatum, which we have shown to be activated by the self-
administration of cocaine, and more recently by the acute administration of alcohol 
(Herring et al., 2004), will be critical to study since these brain areas receive 
dopaminergic VTA inputs (Newman and Winans, 1980) as well as glutamatergic 
innervation from the amygdala (Kita and Kitai, 1990) and hippocampus (Kelley and 
Domesick, 1982).  
Remarkably, ACh neurotransmission may play an important role not only in 
facilitating addiction, but also in the prevention and treatment of addiction. It has recently 
been reported that ACh facilitates LTP expression in MSNs as well as prefrontal–striatal 
signaling onto MSNs via muscarinic m1 receptors (Calabresi et al., 1999; Alcantara et al., 
2001). The prefrontal cortex exerts an executive function over a variety of cortical and 
subcortical structures, and may have an important influence in either driving or 
attenuating compulsive drug seeking behavior and relapse. Therefore, cholinergic 
interneurons may serve to (1) facilitate the striatal functions that drive addiction and (2) 
mediate prefrontal–striatal signaling onto MSNs involved in either the facilitation or 
attenuation of addiction-related behaviors (see Fig. 2.4). It is critical to study and 
understand the specific microcircuitry and molecular signaling pathways of the 
cholinergic neuronal network system, especially as they pertain to incoming 
glutamatergic prefronto-striatal neurotransmission. Furthermore, it is also important to 
focus on identifying areas that are especially susceptible to plasticity and learning. 
Finally, because this microcircuitry is located at the interface of the striatum and the 
prefrontal cortex, which is an area involved in executive function, it may be an important 
site to focus on when designing improved pharmaceutical and behavioral programs 
designed for the treatment and prevention of drug abuse and addiction.  
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Chapter 3: Dopamine D5 Receptor Localization on Cholinergic Neurons 
of the Rat Forebrain and Diencephalon: A Potential Neuroanatomical 
Substrate Involved in Mediating Dopaminergic Influences on 
Acetylcholine Release 
3.1 Abstract 
The study of dopaminergic influences on acetylcholine release is especially useful 
for the understanding of a wide range of brain functions and neurological disorders, 
including schizophrenia, Parkinson’s disease, Alzheimer’s disease, and drug addiction. 
These disorders are characterized by a neurochemical imbalance of a variety of 
neurotransmitter systems, including the dopamine and acetylcholine systems. Dopamine 
modulates acetylcholine levels in the brain by binding to dopamine receptors located 
directly on cholinergic cells. The dopamine D5 receptor, a D1-class receptor subtype, 
potentiates acetylcholine release and has been investigated as a possible substrate 
underlying a variety of brain functions and clinical disorders. This receptor subtype, 
therefore, may prove to be a putative target for pharmacotherapeutic strategies and 
cognitive-behavioral treatments aimed at treating a variety of neurological disorders. The 
present study tested the hypothesis that cholinergic cells in the dopamine targeted areas 
of the cerebral cortex, striatum (dorsal striatum and nucleus accumbens), basal forebrain, 
and diencephalon express the dopamine D5 receptor. These receptors were localized on 
cholinergic neurons with dual labeling immunoperoxidase or immunofluorescence 
procedures using antibodies directed against choline acetyltransferase (ChAT) and the 
dopamine D5 receptor. Results from this study support previous findings indicating that 
striatal cholinergic interneurons express the dopamine D5 receptor. In addition, 
cholinergic neurons in other critical brain areas also show dopamine D5 receptor 
expression. Dopamine D5 receptors were localized on the somata, dendrites, and axons of 
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cholinergic cells in each of the brain areas examined. These findings support the 
functional importance of the dopamine D5 receptor in the modulation of acetylcholine 
release throughout the brain.  
3.2 Introduction 
Several major cholinergic systems exist in the rat brain, including the cholinergic 
interneurons of the cerebral cortex (Houser et al., 1985) and the striatum (Butcher and 
Woolf, 1982; Bolam et al., 1984), as well as the projection neurons arising from the basal 
forebrain (Zaborszky et al., 1993) and the diencephalon (Manger et al., 2002). 
Cholinergic neurons in each of these systems form intricate networks necessary for a 
number of critical functions, including cognition, motivation, learning and memory, and 
motor functions (Mesulam et al., 1983; Woolf, 1991; Kasa et al., 1997; Pisani et al., 
2003). Dopaminergic innervation of these cholinergic brain regions occurs primarily 
through the dopamine (DA) afferents arising from the mesencephalon, more specifically 
the ventral tegmental area (VTA) and the substantia nigra (SN) (Swanson, 1982). 
Furthermore, evidence of dopaminergic modulation of cholinergic neurotransmission has 
been previously reported (Day and Fibiger, 1992; De Boer et al., 1992; Day and Fibiger, 
1993; Imperato et al., 1993). The focus of this study was to localize DA D5 receptors, a 
DA D1-class receptor subtype, on cholinergic neurons of the cerebral cortex, striatum, 
basal forebrain, and the diencephalon (see Fig. 3.1), which may serve as potential neural 
substrates involved in mediating dopaminergic influences on acetylcholine (ACh) release.  




Figure 3.1. Cholinergic cell localization in the rat brain. Schematic coronal sections of 
the rostral-caudal axis of the rat brain show the regions where DA D5-positive 
cholinergic neurons (indicated by dots) were found. Cholinergic cells located in the rat 
forebrain cortices at Bregma 2.70 mm and neostriatum at Bregma 1.20 mm are 
interneurons, whereas cholinergic cells located in the basal forebrain at Bregma 0.20 mm 
and -1.30 mm, and in the basal forebrain and diencephalon at Bregma -2.80 mm are 
projection neurons. 
 
The cerebral cortex of the rat not only receives dense cholinergic innervation from 
projection neurons of the basal forebrain, but also has an intrinsic source of ACh 
provided by local cholinergic interneurons, which provide up to 30% of the total 
cholinergic innervation of the cerebral cortex (Mesulam et al., 1983; Houser et al., 1985). 
The specific role of these local cortical neurons has not been clearly defined, which may 
be due to the difficulty in selectively targeting cholinergic cells for analysis in the cortex. 
Saporin-induced lesions of cholinergic fibers of the cerebral cortex, for example, may 
target not only intrinsic cholinergic cells, but also cholinergic projections from the basal 
forebrain (Dalley et al., 2004). The cortex receives extensive mesencephalic 
dopaminergic innervation (Berger et al., 1974); however, direct evidence of DA synapses 
onto cortical ACh-containing interneurons has not been reported. It is unclear, therefore, 
whether DA modulation of ACh release from these cortical neurons occurs through 
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synaptic or nonsynaptic (i.e., volume transmission) mechanisms or possibly through a 
combination of both types of mechanisms. The localization of DA D5 receptors on these 
cells suggests specific receptor-guided mechanisms involved in ACh release from these 
local circuit neurons. More precise characterization of DA-ACh interactions and the 
functional role of these ACh-containing neurons in the cerebral cortex, however, remain 
to be further investigated. 
Acetylcholine in the striatum is supplied predominantly from large, intrinsic 
cholinergic interneurons, which account for 2% of the entire striatal neuronal 
population. These neurons and their functions, unlike the cholinergic neurons of cerebral 
cortex, have been well characterized. Striatal cholinergic neurons have been implicated in 
such phenomena as long-term potentiation (LTP), synaptic plasticity, and associative 
learning (Aosaki et al., 1994). These cells have further been reported to modulate LTP 
expression in striatal projection neurons (Calabresi et al., 1999) and prefronto-striatal 
information processing (Alcantara et al., 2001) as well as overall striatal signaling (Howe 
and Surmeier, 1995). Striatal cholinergic interneurons are targeted by several 
neurotransmitter systems including the DA mesencephalic system. Dimova et al. (1993) 
reported that striatal cholinergic cells receive direct synaptic contact from tyrosine 
hydroxylase (TH)-positive nerve terminals. DA receptors located on cholinergic neurons, 
therefore, may influence ACh release in the striatum through synaptic as well as possible 
nonsynaptic mechanisms. Further studies have reported the involvement of specific DA 
receptor subtypes in cholinergic neuronal function. The induction of LTP in striatal 
cholinergic neurons, for example, has been reported to be DA D5 receptor-dependent 
(Suzuki et al., 2001). Imbalances in DA-ACh levels in the striatum and other forebrain 
structures, conversely, have been implicated in such disorders as schizophrenia (Sarter 
and Bruno, 1998; Holt et al., 1999), Parkinson's disease (Rinne et al., 1989; Pisani et al., 
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2003), Alzheimer's disease (Gsell et al., 2004), and addiction (Consolo et al., 1999; Mark 
et al., 1999; Berlanga et al., 2003; Herring et al., 2004). 
The cholinergic projection systems of the basal forebrain and the diencephalon 
innervate a variety of structures and, as a result, affect a wide variety of functions. The 
cholinergic neurons of the basal forebrain send dense projections to the cerebral cortex, 
hippocampus, amygdala, and the olfactory bulb (Zaborszky et al., 1993), mediating such 
functions as attention, arousal, motivation, and learning (Dekker et al., 1991; Fibiger, 
1991; Muir et al., 2001). Similarly, cholinergic cells of the diencephalon, namely, the 
medial habenular nucleus, project to the interpeduncular nucleus and, in addition to 
controlling behaviors such as arousal, also regulate sleep cycles and the coordination of 
limb movement (Sutherland, 1982). Both the basal forebrain and diencephalic cholinergic 
projection systems receive dopaminergic input from the mesencephalon (Fallon and 
Moore, 1978; Phillipson and Pycock, 1982; Zaborszky et al., 1993), with the 
diencephalon receiving only a small percentage of DA from local DA neurons (Eaton et 
al., 1994). Furthermore, degeneration of the basal forebrain and its related circuitry is 
pivotal to memory loss observed in such clinical disorders as Alzheimer's disease and 
dementia (Bartus et al., 1982; Kasa et al., 1997). Habenular lesions, on the other hand, 
result in cognitive deficits, specifically, impairments in spatial memory, which is a 
behavior associated with schizophrenia (Lecourtier et al., 2004). 
Dopamine modulates cholinergic activity throughout these systems via two 
general classes of DA receptors, the D1-class (D1 and D5 receptor subtypes) and the D2-
class (D2, D3, and D4 receptor subtypes), which exert their biological effects via G-
protein-coupled intracellular signaling pathways (Missale et al., 1998). The DA D1 
receptor potentiates ACh release (Consolo et al., 1987; Damsma et al., 1990; Imperato et 
al., 1992; Acquas and Di Chiara, 1999) and a similar stimulatory effect on ACh release 
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has been reported for the DA D5 receptor (Hersi et al., 2000). In contrast, DA D2-class 
receptors attenuate ACh release (Stoof et al., 1987; Bertorelli and Consolo, 1990). 
Northern blot analysis and in situ hybridization studies have reported DA D5 
mRNA localization in limbic areas of the brain (Sunahara et al., 1991). Some of the 
highest levels of DA D5 mRNA (Yan and Surmeier, 1997) and receptor protein (Bergson 
et al., 1995) are found in striatal cholinergic interneurons along with very low levels of 
DA D1 mRNA (Le Moine et al., 1990; Yan and Surmeier, 1997; Nicola et al., 2000). 
Immunocytochemical localization of DA D5 receptors on striatal cholinergic neurons has 
been previously described (Rivera et al., 2002); however, DA D5 receptors have not been 
previously localized on any of the other cholinergic circuits investigated in the present 
study. Cholinergic interneurons also highly express the DA D2 receptor in the striatum 
(Alcantara et al., 2003). The high percentage of striatal cholinergic neurons reportedly 
expressing DA D5 and D2 receptors suggests that the majority of these neurons 
coexpress both receptor subtypes. Dopamine D1- and D2-class receptors can produce 
opposing, and occasionally synergistic effects at the cellular/molecular and behavioral 
levels (Stoof and Kebabian, 1981; Bertorello et al., 1990; Svenningsson et al., 2000; 
Fetsko et al., 2003). The synergistic effects associated with the colocalization of DA D1- 
and D2-class receptors in particular may contribute to the intracellular mechanisms that 
are critical for such phenomena as plasticity and learning (Kashihara et al., 1999; Silkis, 
2001). 
Given the evidence supporting the importance of DA D1-class receptor-mediated 
dopaminergic modulation of cholinergic neurotransmission (Acquas and Di Chiara, 
2001), the present study investigated the neuroanatomical localization of the DA D5 
receptor on cholinergic neurons of the rat forebrain and diencephalon. Dual labeling 
immunoperoxidase or immunofluorescence procedures, using antibodies directed against 
choline acetyltransferase (ChAT) and the DA D5 receptor, were employed. Localization 
of the DA D5 receptor within these cholinergic networks provides evidence in support of 
a specific role for this receptor subtype in ACh release and, furthermore, will provide a 
better understanding of the neural mechanisms that underlie DA-ACh-mediated 
behaviors and related clinical disorders. (This study has been published: Berlanga, et al. 
2005). 
3.3 Methods   
Tissue from eight adult male Sprague-Dawley rats (Simonsen Labs, Gilroy, CA) 
was used for dual immunoperoxidase or dual immunofluorescence procedures in this 
study. All efforts were made to minimize animal suffering and the number of animals 
used in the present study. Experimental procedures conformed to National Institutes of 
Health guidelines and were carried out under an institutionally reviewed and approved 
research protocol. 
3.3.1 Animals 
Eight Sprague-Dawley rats were used in this study. Six rats were used for the 
immunoperoxidase quantification procedures and two animals were used for the dual 
immunofluorescence procedures.  
3.3.2 Tissue Preparation 
Animals were administered an overdose of sodium pentobarbital (Nembutal; 100 
mg/kg i.p.) and perfused transcardially with 60 ml of 0.1 M phosphate-buffered saline 
(PBS), pH 7.4, followed by 200 ml of 4% paraformaldehyde/0.1% glutaraldehyde in 
PBS, pH 7.4. The brains were removed and postfixed for 2 hours in 4% 
paraformaldehyde in PBS. Coronal sections were taken at a thickness of 100 m on a 
vibratome, placed in 15% sucrose in PBS, and frozen in liquid nitrogen. Tissue sections 
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were then thawed and processed for light microscopy using single- or dual-labeling 
immunoperoxidase or immunofluorescence procedures for the DA D5 receptor and 
ChAT.  
3.3.3  Dual Immunocytochemistry 
Dopamine D5 receptor and ChAT dual immunoperoxidase labeling 
Light microscopy dual labeling immunoperoxidase procedures were performed on 
free-floating, coronal tissue sections which were rinsed in 0.1 M PBS (2 × 10 minutes, 3 
× 5 minutes) and preincubated for 1 hour in a PBS blocking solution containing 5% 
normal horse serum (NHS) and 0.01% hydrogen peroxide. Sections were then incubated 
simultaneously in a cocktail of both primary antibodies: affinity purified goat anti-
dopamine D5 receptor polyclonal antibody (1:500; Chemicon, Temecula, CA) and 
affinity-purified mouse anti-ChAT monoclonal antibody (1:1,000; Chemicon) for 24 
hours at 4°C. The DA D5 receptor polyclonal antibody is specific for the DA D5 receptor 
and exhibits no cross-reactivity with the DA D1 receptor or any other DA receptor types 
(Grandy et al., 1991; Sunahara et al., 1991; Tiberi et al., 1991). Sections were rinsed in 
PBS (3 × 5 minutes; and similarly rinsed after each step). The tissue was then incubated 
in secondary biotinylated donkey anti-mouse IgG antiserum (1:500; Jackson 
ImmunoResearch, West Grove, PA), diluted in PBS solution and 2% NHS for 2 hours. 
Subsequently, the tissue was incubated in an avidin-biotin peroxidase complex (ABC) 
(Vectastain Elite Kit; Vector, Burlingame, CA) for 1 hour. ChAT-immunoreactivity (IR) 
was visualized with 0.05% 3,3 -diaminobenzidine tetrahydrochloride (DAB) and 0.01% 
H2O2 in PBS, which resulted in a brown reaction product. The development time of DAB 
was minimal, so as not to obscure the second label. Sections were subsequently incubated 
in secondary biotinylated horse anti-goat IgG antiserum (1:200; Vector), diluted in PBS 
solution and 2% NHS for 1 hour, and then incubated in the ABC complex for 1 hour. 
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Dopamine D5 receptor-IR was visualized with the Vector SG substrate kit, resulting in a 
blue reaction product. 
In order to verify the specificity of the ChAT/DAB and D5/SG dual labeling 
procedures, all combinations of single-labeled ChAT and DA D5 receptor visualized with 
either DAB or Vector SG were employed. Specific labeling for the respective antigens 
was observed in all of these procedures. Specifically, the two antibodies (ChAT and D5) 
were first processed as single labels to ensure that the individual labels were labeling 
specific cells in appropriate brain areas as previously reported in the literature. Once 
antibody specificity was verified, the antibodies were then used together to label DA D5 
receptors on cholinergic neurons. Control sections for single- and dual-labeling 
procedures were processed identically with the exception that primary antibodies were 
omitted from the incubation solution. Single labeling was observed when one of the 
primary antibodies was omitted, and no staining was detected in the absence of both 
antibodies. 
Two primary DA D5 receptor antibodies were used in this study for 
immunoperoxidase or immunofluorescence procedures. The DA D5 receptor antibody 
from Santa Cruz Biotechnology (Santa Cruz, CA) recognizes an 18-amino acid sequence 
(amino acids 455-472) on the carboxy terminal region of the fourth cytoplasmic loop 
(Ricci et al., 2001). This antibody recognizes a single band of appropriate molecular 
weight, 51 kDa, and shows the same general labeling pattern in tissue processed using the 
DA D5 receptor antibody from Chemicon, which recognizes a 19-amino acid sequence 
(amino acids 455-473) on the carboxy terminal region of the fourth cytoplasmic loop of 
the DA D5 receptor. All brain regions in this study were identified using The Rat Brain in 
Stereotaxic Coordinates by Paxinos and Watson (1998). The photomicrographs in each 
figure correspond to specific brain atlas illustrations included in Figures 3.1-3.6. All 
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photomicrograph images were processed for contrast and brightness with Adobe 
PhotoShop (San Jose, CA).  
3.3.4 Dual Immunofluorescence 
Dopamine D5 receptor and ChAT dual immunofluorescence labeling 
Light microscopy dual labeling immunofluorescence procedures were performed 
on free-floating, coronal tissue sections. Sections were rinsed in 0.1 PBS (2 × 10 minutes, 
3 × 5 minutes) and preincubated for 1 hour in a PBS blocking solution containing 5% 
normal donkey serum (NDS). Sections were then incubated simultaneously in a cocktail 
of both primary antibodies: affinity-purified goat anti-dopamine D5 receptor polyclonal 
antibody (1:50; Santa Cruz Biotechnology) and affinity-purified mouse anti-ChAT 
monoclonal antibody (1:1,000; Chemicon) for 48 hours at 4°C. Sections were rinsed in 
PBS (3 × 5 minutes). The tissue was then incubated in a cocktail of both secondary 
antibodies: Fluorescein (FITC) affinipure donkey anti-mouse IgG and Texas Red 
affinipure donkey anti-goat IgG (1:500; Jackson ImmunoResearch), diluted in PBS 
solution and 2% NDS for 1 hour. Sections were washed with PBS (3 × 5 minutes) and 
placed back in the primary cocktail for 1 hour followed by incubation in the secondary 
cocktail for 1 hour. The incubation in primary and secondary cocktails was repeated a 
third time with washes (PBS 3 × 5 minutes) between each hour incubation. The sections 
were then mounted and dried overnight and then coverslipped with Krystalon (EM 
Science Harleco, Gibbstown, NJ) mounting media. Control sections for dual labeling 
procedures were processed identically with the exception that primary antibodies were 
omitted from the incubation solution. Single labeling was observed when one of the 
primary antibodies was omitted, and no staining was detected in the absence of both 
antibodies. 
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Images were captured with a 40× objective (numerical aperture 1.25) using a 
Leica TCS 4D confocal laser-scanning microscope. FITC immunofluorescence was 
visualized with an excitation wavelength of 488 nm using an argon laser and Texas Red 
immunofluorescence was visualized with an excitation wavelength of 594 nm using an 
HeNe laser. Channels were acquired sequentially. FITC emission was collected between 
500-570 nm. Texas Red emission was collected between 600-700 nm. 
3.3.5 Quantitative Analysis 
Quantitative analysis of cholinergic neurons was performed on dual ChAT/D5 
immunoperoxidase-labeled tissue. Three digital images representing areas of 0.45 mm2 
were acquired from each of the brain areas of interest using a 10× objective on a Nikon 
Eclipse E800 light microscope. Each brain region was carefully identified based on 
reliable neuroanatomical landmarks using the atlas of Paxinos and Watson (Paxinos and 
Watson, 1998). Images were stored and analyzed. The percentage of cholinergic cells that 
expressed DA D5 IR was calculated for each sample area. An average number for the 
three sample areas per brain region was calculated for each animal. The group averages 
were subsequently calculated for each brain area of interest. The data are expressed as the 
mean and standard error of the mean (SEM) in Table 3.1.  
3.4 Results 
Dopamine D5 receptor labeling was detected on cholinergic neurons in each of 
the brain areas examined using dual labeling immunoperoxidase or immunofluorescence 
procedures. Both immunocytochemistry (ICC) procedures identified DA D5 labeling on 
cholinergic cell somata and dendrites. The immunoperoxidase procedure additionally 
provided the necessary cellular resolution to detect DA D5 labeling on axonal fibers. 
Quantitative analysis of ChAT/D5 coexpression reported in Table 3.1 was calculated 
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from immunoperoxidase-labeled tissue. The incidence of dual ChAT/D5 labeling and 
single ChAT or D5-labeled cells and fibers using the immunofluorescence procedure is 
reported for each brain area. Confocal laser immunofluorescence photomicrographs for 
five representative brain areas are presented. These areas include the primary motor 
cortex (M1) from the cerebral cortex, dorsal striatum (DS) from the neostriatum, 
horizontal diagonal band (HDB) and internal capsule/lateral globus pallidus (IC/LGP) 




















Table 1. Percentages of Cholinergic Neurons That 
Expressed the Dopamine D5 Receptor1
Brain region 
ChAT/D5 dual-
labeled cells (%) 
Cerebral cortex  
   Infralimbic (IL) 68 ± 7 
   Prelimbic (PrL) 80 ± 4 
   Cingulate (Cg1) 59 ± 5 
   Motor  
      Primary (M1) 60 ± 5 
      Secondary (M2) 61 ± 6 
   Somatosensory  
      Primary (S1) 79 ± 6 
   Granular insular (GI) 73 ± 6 
   Agranular insular (AI) 75 ± 6 
Neostriatum  
   Dorsal striatum (DS) 93 ± 6 
   Nucleus accumbens (NAcc)  
      Shell (Sh) 75 ± 10 
      Core (C) 85 ± 3 
   Islands of calleja (ICj) 79 ± 5 
   Olfactory tubercle (Olf) 75 ± 10 
Basal forebrain  
   Medial septal nucleus (MS) 81 ± 4 
   Vertical diagonal band (VDB) 72 ± 3 
   Horizontal diagonal band (HDB) 78 ± 3 
   Ventral pallidum (VP) 83 ± 5 
   Internal capsule/lateral globus 
pallidus (IC/LGP) 
93 ± 3 
   Substantia innominata (SI) 88 ± 5 
   Magnocellular preoptic area 
(MCPO) 
95 ± 3 
   Ansa lenticularis (AL) 71 ± 7 
Diencephalon  
   Medial habenula (MHB) 99 ± 0 
   Medial globus pallidus (MGP) 86 ± 11 
   Rostral lateral hypothalamus 
(LH) 
82 ± 7 
 
Table 3.1 
1 The values listed reflect the group means and 
standard errors for the percent of cholinergic cells that 
expressed the DA D5 receptor for each brain region. 




Cholinergic interneurons of the cerebral cortex 
Dopamine D5 receptor and ChAT dual immunoperoxidase labeling was examined 
in the infralimbic (IL), prelimbic (PrL), cingulate (Cg1), primary and secondary motor 
(M1 and M2), primary somatosensory (S1), granular insular (GI), and agranular insular 
(AI) cortices (Fig. 3.2A,B). Dopamine D5 receptor immunolabeling was present on the 
somata, dendrites, and axons of cortical cells within all of these cortical regions. 
Dopamine D5 receptor labeled fibers were observed in cortical layer I, the molecular 
layer of the cortex, which reportedly contains primarily cell processes and few cell 
bodies. Approximately 68% of the cholinergic cells in the IL cortex and 80% of the 
cholinergic cells in the PrL cortex revealed DA D5 receptor labeling. ChAT and DA D5 
coexpression in the IL and PrL was observed primarily in layers II and III, with a few 
dual-labeled cells appearing occasionally in layers V and VI (Fig. 3.2C,E). Higher-
magnification images of cells selected from the IL and PrL appear in Figure 3.2D,F, 
respectively. Quantification of dual-labeled cells in the Cg1 cortex revealed that 59% of 
the ChAT-positive cells were DA D5-positive. Dual-labeled cells were present in layers 
II-VI, with the highest density observed in layers II and III (Fig. 3.2G). A higher-
magnification image of a dual-labeled cell from Cg1 is shown in Figure 3.2H. Dopamine 
D5-IR on ChAT-positive cells was evident in the primary and secondary motor cortices. 
Approximately 61% of the cholinergic cells in M2 and 60% in M1 revealed DA D5 
receptor-IR (Fig. 3.2I-L). Dual immunofluorescence labeling procedures confirmed 
colocalization of the DA D5 receptor on cholinergic neurons and other cortical 
noncholinergic cells including large cells in layer V believed to be pyramidal cells in all 
of the cortical areas examined. Representative confocal laser photomicrographs from M1 
cortex demonstrate coexpression of DA D5 and ChAT (Fig. 3.2M-O). Cholinergic cells 
with somatic and dendritic DA D5 receptor labeling were found throughout all layers of 
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S1 (Fig. 3.2P,Q). Quantification of dual-labeled cells in S1 revealed 79% of the ChAT 
cells in this cortical area were DA D5-positive. ChAT-positive cells were also found 
throughout all layers of GI and AI cortices, and these cells also exhibited DA D5 receptor 
labeling on their somata and dendrites (Fig. 3.2R-U). Approximately 73% of the ChAT-
positive cells in the GI and 75% of the ChAT cells in the AI were DA D5-positive. 
 
 





Figure 3.2 (continued). 
 
 
Figure 3.2 (continued). Photomicrographs of tissue from the cerebral cortex of the rat 
forebrain. A-H: Tissue was labeled for ChAT and DA D5 receptor using a dual labeling 
immunoperoxidase procedure. A: Schematic coronal section from the Paxinos and 
Watson atlas (Bregma 2.70 mm) identifies the cortical subregions of the rat forebrain 
where cholinergic neurons were examined. B: A low-magnification photomicrograph of a 
coronal section from the rat forebrain corresponding to the schematic in A. C: Dual 
immunoperoxidase labeled tissue revealed ChAT-IR cholinergic interneurons (brown) 
and DA D5 receptor labeling (blue) in the IL, PrL, and Cg1 cortices. Dopamine D5 
receptor containing cholinergic neurons were observed primarily in layers II and III and 
occasionally in layers V and VI of the IL, PrL and Cg1. Representative dual-labeled cells 
from the IL, PrL, and Cg1 cortices (indicated by the boxes and black arrows) are shown 
at a higher magnification in D, F, and H. These cells reveal DA D5 receptor labeling 
(blue; black arrows) on the cell somata and process of the cholinergic neurons (brown) 
(D,F,H). IL, infralimbic cortex; PrL, prelimbic cortex; Cg1, cingulate cortex; M2, 
secondary motor cortex; M1, primary motor cortex; S1, primary somatosensory cortex; 
GI, granular insular cortex; AI, agranular insular cortex. I-S: Photomicrographs of tissue 
processed using dual labeling immunocytochemistry procedures revealed cholinergic 
interneurons (brown) and DA D5 receptor labeling (blue) in M2 (I), M1 (K), S1 (P), and 
GI (R) cortices. Dopamine D5 receptor containing cholinergic neurons were observed in 
cortical layers II through VI of M2 (I), M1 (K), S1 (P), and GI (R) cortices. 
Representative cells from M2, M1, S1, and GI (indicated by the boxes and black arrows) 
are shown at higher magnification (J,L,Q,S). Higher-magnification images of each cell 
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reveal DA D5 receptor labeling (blue; black arrows) on the cell bodies and processes of 
cholinergic neurons (brown) of M2 (J), M1 (L), S1 (P), and GI (R). High-magnification 
photomicrographs of dual immunofluorescence confocal laser photomicrographs from 
layer V of M1 reveal ChAT-IR neurons (FITC/green) (M) and DA D5 receptor labeled 
cells (Texas Red) (N). Coexpression of ChAT and D5 in these neurons is evident by the 
yellow label (O). White arrows indicate cells that revealed dual labeling and a white 
asterisk indicates a ChAT-IR cell that did not express the DA D5 receptor. M2, secondary 
motor cortex; M1, primary motor cortex; S1, primary somatosensory cortex; GI, granular 
insular cortex; ChAT, choline acetyltransferase; DA D5R, dopamine D5 receptor; LV, 
cortical layer five. T,U: Photomicrographs of tissue processed using dual labeling 
immunoperoxidase procedures revealed ChAT-IR neurons (brown) and DA D5 receptor 
labeling (blue) in the AI (T). Dopamine D5 receptor localization on cholinergic neurons 
was observed in layers II through VI of AI. A representative cell from the AI cortex 
(indicated by the box and black arrow) is shown at a higher magnification in U. A higher-
magnification photomicrograph of the cell reveals DA D5 receptor labeling (blue; black 
arrows) on the cell body and process of the cholinergic neuron (brown) (U). AI, agranular 
insular cortex. Scale bars = 500 m in B; 100 m in C,E,G,T; 5 m in D,F,H,J,L,Q,S,U; 
200 m in I,K,P,R; 15 m in M-O. 
 
Cholinergic interneurons of the striatum, nucleus accumbens, islands of Calleja, and 
olfactory tubercle 
Cholinergic interneurons located in the dorsal striatum (DS) and nucleus 
accumbens (NAcc), including the shell (Sh) and core (C) compartments, as well as the 
neurons of the islands of Calleja (ICj) and the olfactory tubercle (Olf) (Fig. 3.3A,B) were 
found to express the DA D5 receptor on cell somata, dendrites, and axons. Dual-labeled 
cells were scattered throughout the DS and occasionally formed cell clusters. ChAT-IR 
axons in the striatum, distinguishable from dendrites based on a smaller diameter (axons 
measure less than 1 micron, whereas dendrites measure 1 micron or greater), prominent 
axonal varicosities, and a dense axonal arborization, revealed DA D5 labeling (Fig. 
3.3C). The diameter of the axon illustrated in Figure 3.3C was estimated to be 0.6 m, 
whereas dendrites found in the same area had diameters of 1.5 m. The presence of DA 
D5 receptor labeling was specifically localized on the varicosities of dual-labeled axons. 
The somata of striatal cholinergic interneurons stained heavily for the DA D5 receptor 
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and the dendrites of these cells revealed further labeling at circumscribed sites along the 
fibers. Quantification of dual-labeled cells revealed that 93% of ChAT labeled cells in the 
DS coexpressed the DA D5 receptor (Fig. 3.3D). Dual immunofluorescence labeling 
procedures confirmed localization of the DA D5 receptor on cholinergic neurons in the 
striatum, NAcc, ICj, and Olf. Representative confocal laser photomicrographs of the DS, 
demonstrate coexpression of DA D5 and ChAT (Fig. 3.3E,F). The immunofluorescence 
procedure also revealed DA D5 receptor labeling on other noncholinergic striatal cells, 
which presumably include medium spiny projection neurons (MSNs) and other 
interneurons. Similarly, single DA D5-labeled cells were also evident in the NAcc, ICj, 
and Olf. In the NAcc, 75% of the cholinergic neurons in the shell and 85% in the core 
were dual-labeled for ChAT and DA D5 (Fig. 3.3G,H). Cholinergic striatal interneurons 
in the DS were larger compared to cells in the shell and core compartments of the NAcc; 
however, cholinergic neurons frequently formed small clusters within the shell and core 
compartments. Approximately 79% of the cholinergic cells in the ICj and 75% in the Olf 
also showed dual labeling (Fig. 3.3I,J). Dual-labeled cells in the ICj were tightly 
clustered and typically smaller than striatal neurons. 




Figure 3.3. Dopamine D5 receptor localization on cholinergic neurons of the 
neostriatum.  Photomicrographs from the neostriatum of the rat brain. Tissue was 
labeled for ChAT and DA D5 receptor using dual labeling immunocytochemistry 
procedures. A: Coronal section from the Paxinos and Watson atlas indicating the areas 
where photomicrographs were taken of the neostriatum of the rat (Bregma 1.20 mm). B: 
A low-magnification photomicrograph of a ChAT/D5 immunolabeled coronal section 
corresponding to the schematic in A. C: A high-magnification photomicrograph of a 
dual-labeled axon from the dorsal striatum. Varicosities present on the neuronal process 
are typical characteristics of striatal axons. Arrows indicate DA D5 receptor labeling 
(blue) on the ChAT-IR cholinergic axon (brown). Receptor labeling was largely 
associated with the varicose regions of the axon. D: Photomicrograph of a cholinergic 
interneuron from the dorsal striatum. Dual immunolabeling revealed DA D5 receptor 
labeling (blue; black arrows) on cholinergic cells and on circumscribed regions of the 
cholinergic somata and dendritic processes. Confocal laser scanning photomicrographs 
show a neuron in the dorsal striatum that coexpressed ChAT (FITC/green) (E) and the 
DA D5 receptor (Texas Red) (F). White arrows indicate a dual-labeled ChAT/D5 cell. A 
few single-labeled D5-positive (noncholinergic) neurons are also visible in F. Dual 
ChAT/D5 immunolabeled cells were observed in the shell (G), and core compartments of 
the NAcc (H), island of Calleja (I), and olfactory tubercle (J). Black arrows indicate DA 
D5 receptor labeling (blue) on cholinergic cells (brown). DS, dorsal striatum; Sh, shell of 
the NAcc; C, core of the NAcc; ICj, island of Calleja; Olf, olfactory tubercle; ChAT, 
choline acetyltransferase; DA D5R, dopamine D5 receptor. Scale bars = 500 m in B; 4 
m in C; 20 m in D-J. 
 
Cholinergic cells of the basal forebrain 
The basal forebrain of the rat is made up of a collection of structures including the 
medial septal nucleus (MS), vertical diagonal band (VDB), horizontal diagonal band 
(HDB), ventral pallidum (VP), internal capsule (IC), lateral globus pallidus (LGP), 
substantia innominata (SI), magnocellular preoptic area (MCPO), and the ansa 
lenticularis (AL). Dopamine D5 receptor localization on cholinergic neurons was 
detected using dual labeling immunoperoxidase or immunofluorescence methods in each 
of these areas of the basal forebrain (Figs. 3.4-3.6). 
Medial septal nucleus 
The medial septal nucleus contained cells that were primarily round and small and 
were positioned in dense neuronal clusters (Fig. 3.4A,B). Dopamine D5 receptor labeling 
was evident on the somata and dendrites of cholinergic cells located within the MS (Fig. 
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3.4C). Quantification of dual-labeled cells revealed that 81% of the cholinergic cells in 
the MS expressed the DA D5 receptor. ChAT-IR axonal fibers exhibiting DA D5 
receptor labeling were also noted in this area. Many single DA D5-labeled fibers and 
cells were observed in this region. 
Vertical and horizontal limbs of the diagonal band 
Cholinergic projection cells were positioned in dense neuronal clusters (Fig. 3.4B) 
in the limbs of the VDB (Fig. 3.4D) and HDB (Fig. 3.4E). The cells appeared to be small 
and the somata were generally round, with extensive visible fibers, similar to the 
cholinergic cells of the MS. Approximately 72% of cholinergic cells in the VDB and 
78% in the HDB revealed dense DA D5 receptor labeling. Dual-labeled varicose axonal 
fibers were also evident in this area. Dual labeling immunofluorescence procedures 
confirmed the presence of the DA D5 receptors on cholinergic neurons in all areas of the 
basal forebrain. Representative confocal laser photomicrographs of the HDB demonstrate 
coexpression of DA D5 and ChAT (Fig. 3.4F,G). The immunofluorescence procedure 




Figure 3.4. Dopamine D5 receptor localization on cholinergic neurons of the rostral 
basal forebrain.  Photomicrographs from the basal forebrain. Tissue was labeled for 
ChAT and DA D5 receptor using dual labeling immunocytochemistry procedures. A: 
Coronal section from the Paxinos and Watson atlas indicating the areas where 
photomicrographs were taken from the basal forebrain (Bregma 0.20 mm). B: A low-
magnification photomicrograph taken of a coronal section corresponding to the schematic 
in A. Dual ChAT/D5 immunolabeled cells were observed in the medial septal nucleus 
(C), vertical limb of the diagonal band (D), and horizontal limb of the diagonal band (E). 
Black arrows indicate DA D5 receptor labeling (blue) on cholinergic cells (brown). F,G: 
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A pair of dual immunofluorescence confocal laser photomicrographs from the horizontal 
limb of the diagonal band revealed cells that coexpressed ChAT (FITC/green) (F) and the 
DA D5 receptor (Texas Red) (G). White arrows indicate the dual-labeled neurons. A few 
single-labeled ChAT-IR neurons are visible in F and a few single-labeled D5-positive 
neurons and fibers are visible in G. Photomicrograph of a cholinergic cell from the 
ventral pallidum (H) also revealed DA D5 labeling (blue; black arrows) on cholinergic 
neurons (brown). MS, medial septal nucleus; VDB, vertical diagonal band; HDB, 
horizontal diagonal band; VP, ventral pallidum; ChAT, choline acetyltransferase; DA 
D5R, dopamine D5 receptor. Scale bars = 500 m in B; 10 m in C-E,H; 20 m in F,G. 
 
Ventral pallidum 
The morphology and size of VP cholinergic cells were similar to those in the 
diagonal band and the MS. These cells were typically positioned in clusters; however, 
they were not situated in dense clusters as those observed in the MS and diagonal band. 
Dopamine D5 receptor labeling was visible on the somata and dendrites of 83% of these 
cells (Fig. 3.4H). Dual-labeled axons were also noted in this area. In addition, many DA 
D5 single-labeled fibers and cells were also observed in this region. 
Internal capsule and lateral globus pallidus 
The IC and the LGP contained clusters of cholinergic cells (Fig. 3.5A,B). The 
cells were observed to border the edges of the IC and the LGP. Dopamine D5 receptor 
localization was evident on the somata, dendrites, and axons of 93% of ChAT-IR cells of 
this region (Fig. 3.5C). Dual labeling immunofluorescence procedures confirmed 
colocalization of the DA D5 receptor on cholinergic neurons in this area. Representative 
confocal laser photomicrographs of the IC/LGP demonstrate coexpression of DA D5 and 
ChAT (Fig. 3.5D,E). No single DA D5-labeled cells were observed in this region. 
Substantia innominata 
Cells in the SI (Fig. 3.5F) were similar in size and morphology to cholinergic 
neurons of the VP. Dopamine D5 receptor labeling was observed on the somata, 
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dendrites, and axons of 88% of the cholinergic neurons. Dopamine D5 receptor labeling 
was also observed on other noncholinergic cells and fibers in this region. 
Magnocellular preoptic area 
Cells in the MCPO (Fig. 3.5G) were similar in morphology and size to those cells 
observed in the VP and SI. Approximately 95% of cholinergic cells in the MCPO 
revealed DA D5 receptor labeling. Dopamine D5 IR was found on the cell bodies and 
dendrites of those cells. Dopamine D5 receptor labeling was also observed on other 
noncholinergic cells and fibers in this region. 
 
 
     
 
 
Figure 3.5. Dopamine D5 receptor localization on cholinergic neurons of the basal 
forebrain.  Photomicrographs of tissue from the basal forebrain. Tissue was labeled for 
ChAT and DA D5 receptor using dual labeling immunocytochemistry procedures. A: 
Coronal section from the Paxinos and Watson atlas indicating the areas where 
photomicrographs were taken from the basal forebrain (Bregma -1.30 mm). B: A low-
magnification photomicrograph of a dual ChAT/D5-immunolabeled coronal section 
corresponding to the schematic in A. C: A dual-labeled cholinergic neuron located in the 
border between the internal capsule and lateral globus pallidus. A pair of confocal laser 
scanning photomicrographs show dual-labeled neurons located at the border of the IC and 
LGP that were IR for ChAT (FITC/green) (D) and the DA D5 receptor (Texas Red) (E). 
White arrows indicate coexpression of ChAT and D5 in these neurons. Photomicrograph 
of a cholinergic cell from the substantia innominata (F) and the magnocellular preoptic 
area (G) also revealed DA D5 labeling (blue; black arrows) on cholinergic neurons 
(brown). IC, internal capsule; LGP, lateral globus pallidus; SI, substantia innominata; 
MCPO, magnocellular preoptic area; ChAT, choline acetyltransferase; DA D5R, 
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dopamine D5 receptor. Scale bars = 500 m in B; 15 m in C,F; 20 m in D,E; 10 m in 
G. 
Ansa lenticularis 
The AL, which is adjacent to the nigrostriatal bundle, the medial forebrain bundle, 
and the lateral hypothalamus, also contained clusters of cholinergic cells (Fig. 3.6A-C). 
These cells were smaller than cells in the MCPO and were tightly packed together. 
Approximately 71% of the cells in this region coexpressed ChAT and DA D5 receptors. 
These cells exhibited DA D5 receptor labeling on their somata and dendrites. Dual-
labeled axons were also observed in this region. No single DA D5-labeled cells were 
observed in this region. 
Cholinergic cells of the diencephalon 
The cholinergic cells of the diencephalon were spread across three different 
regions, including the medial habenula (MHB), medial globus pallidus (MGP), and 
rostral lateral hypothalamus (LH). Dopamine D5 receptor localization on cholinergic 
neurons was observed in each of these areas using dual labeling immunoperoxidase or 
immunofluorescence procedures (Fig. 3.6). 
Medial habenula 
The greatest cholinergic cell density was observed in the MHB (Fig. 3.6D). Cells 
were small and round and tightly packed together, with few visible fibers. Approximately 
99% of these cells stained for the DA D5 receptor. Labeling on the fibers of these cells 
was difficult to discern because the cells were so tightly packed together. No single DA 
D5-labeled cells were observed in this region. 
Medial globus pallidus 
Cholinergic cells of the MGP (Fig. 3.6E) were similar in size and morphology to 
cells located along the edge of the LGP. Cholinergic cells in the MGP, however, were 
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more evenly distributed in this brain area as compared to the LGP. Dopamine D5 
receptor labeling was observed on the somata, dendrites, and axons of 86% of these 
cholinergic cells as well as on many noncholinergic cells. 
Rostral lateral hypothalamus 
The cholinergic cells of the rostral LH (Fig. 3.6F) were morphologically similar 
and in close proximity to the cholinergic cells of the MGP. Dopamine D5 receptor 
labeling was evident on the somata, dendrites, and axons of 82% of ChAT-IR neurons in 
this region. Dopamine D5 receptors also appeared on noncholinergic neurons in this brain 
area (Fig. 3.6G,H). Dual labeling immunofluorescence procedures confirmed 
colocalization of the DA D5 receptor on cholinergic neurons in this area. Representative 
confocal laser photomicrographs of the LH demonstrate coexpression of DA D5 and 
ChAT (Fig. 3.6G,H). The immunofluorescence procedure also detected DA D5 receptor 






Figure 3.6. Dopamine D5 receptor localization on cholinergic neurons of the basal 
forebrain and diencephalon. Photomicrographs of tissue from the basal forebrain and 
diencephalon. Tissue was labeled for ChAT and DA D5 receptor using dual labeling 
immunocytochemistry procedures. A: Coronal section from the Paxinos and Watson atlas 
indicating the areas where photomicrographs were taken from the basal forebrain and 
diencephalon (Bregma -2.80 mm). B: A low-magnification photomicrograph of a coronal 
section corresponding to the schematic in A. Dual-labeled ChAT/D5-positive cells were 
observed in the ansa lenticularis (C), medial habenula (D), medial globus pallidus (E), 
and the lateral hypothalamus (F). Dopamine D5 receptors (blue; black arrows) labeled the 
somata of cholinergic neurons (brown) in these brain regions. Dopamine D5 receptor 
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labeling was also observed on dendrites of these cells and on axons located within these 
areas. A pair of confocal laser scanning photomicrographs show neurons located in the 
lateral hypothalamus that were dual-labeled for ChAT (FITC/green) (G) and the DA D5 
receptor (Texas Red) (H). White arrows indicate D5-positive cholinergic cells. Single-
labeled DA D5 receptor cells and fibers are also visible in H. AL, ansa lenticularis; MHB, 
medial habenula; MGP, medial globus pallidus; LH, lateral hypothalamus. Scale bars = 
500 m in B; 10 m in C; 5 m in D; 15 m in E,F; 20 m in G,H. 
3.5 Discussion 
The cholinergic systems of the cerebral cortex, striatum, basal forebrain, and 
diencephalon have widespread connections, affecting diverse target structures and a 
myriad of cognitive-, limbic-, and motor-related functions. Results from this study 
revealed that the majority of cholinergic cells in each of these areas express the DA D5 
receptor. More specifically, this study reports DA D5 receptor localization on somata, 
dendrites, and axons of cholinergic cells in each of the brain areas examined. 
Dual labeling immunoperoxidase or immunofluorescence procedures were 
employed in this study to visualize DA D5 receptors on cholinergic cells in the forebrain 
and diencephalon. Tissue from the brainstem and mesencephalon was not included in this 
study, but, given the importance of these cell groups, will be included and examined in 
future studies. Both techniques revealed patterns of labeling that were consistent with 
those reported in the literature for DA D5 IR, ChAT-IR, or coexpression of both in the rat 
brain. For example, striatal cholinergic interneurons, which are known to express among 
the highest DA D5 receptor mRNA (Yan et al., 1997; Yan and Surmeier, 1997) and 
receptor protein levels (Bergson et al., 1995; Rivera et al., 2002) throughout the striatum 
(Nicola et al., 2000) showed a high incidence of DA D5 receptor labeling in the present 
study using either ICC procedure. Noncholinergic striatal cells including MSNs and other 
interneurons that have been reported to express low levels of DA D5 mRNA or D5 
receptor protein (Nicola et al., 2000; Rivera et al., 2002) were detected only by the 
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immunofluorescence procedure. The immunofluorescence procedure detected DA D5 IR 
in noncholinergic cells in most of the brain areas examined with the exception of the 
IC/LGP, AL, and MHB, which did not reveal single DA D5-immunolabeled cells. 
Quantification of the percent of cholinergic neurons that expressed DA D5 labeling 
(presented in Table 3.1) was calculated using the dual labeling immunoperoxidase 
procedure. These values, however, may be considered conservative since this procedure 
appeared to detect DA D5-positive cells only in instances where the cells contained 
sufficiently high levels of the receptor. Among the areas that showed the lowest values of 
DA D5 receptor and ChAT coexpression, using this immunoperoxidase procedure, 
included the cingulate and motor cortices, whereas the highest incidence of DA D5-
positive cholinergic cells was evident in the DS, IC/LPG, MCPO, and MHB. 
The circumscribed localization of DA D5 receptors on cholinergic cells and fibers 
may provide evidence of receptor trafficking and clustering at specific sites along cell 
somata and dendritic and axonal processes of these cells. Evidence of somatic DA D5 
receptor clustering in our study is consistent with reported DA D5 clustering in primate 
cortical pyramidal cells (Paspalas and Goldman-Rakic, 2004). Somatic DA D5 receptor 
immunolabeling may be attributed to the fact that the primary site of protein synthesis is 
believed to take place in the soma, although mounting evidence suggests that translation 
may also occur in axons (Piper and Holt, 2004). Additionally, electron microscopy (EM) 
work by Dimova et al. (1993) reported that striatal cholinergic neurons receive occasional 
synaptic contact from tyrosine hydroxylase (TH)-positive axon terminals on their somata 
and dendrites, with the majority of synapses occurring on proximal cholinergic dendrites. 
Thus, DA D5 receptors may be mediating ACh neurotransmission by clustering at DA 
synaptic sites along the soma and dendritic processes. Pickel and Chan (1990), however, 
reported that only about 1% of TH-positive axons in the striatum and nucleus accumbens 
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are apposed to, or form synapses with, the perikarya or dendrites of ChAT-labeled cells. 
Thus, the major influence on DA receptors located on these cholinergic neurons may be 
nonsynaptically at extrasynaptic sites via volume neurotransmission. Bergson et al. 
(1995) further substantiate this notion through EM evidence of DA D5 receptor 
localization at extrasynaptic sites (Sesack et al., 2003). 
In the present study, some of the cholinergic axons showed DA D5 receptor 
labeling, particularly on axonal varicosities. Cholinergic axons can be identified at the 
light microscopic level based on their small diameter (measuring less than 1 micron), as 
compared to dendrites (measuring 1 micron or greater) (Wainer et al., 1984; Phelps et al., 
1985; Contant et al., 1996), as well as their distinct branching pattern, typically a plexus 
of axonal fibers (Bennett and Wilson, 1999). Further examination of axonal varicosities 
at the EM level revealed the presence of aggregated synaptic vesicles and stereological 
quantification of the volume of varicosities receiving synaptic contact revealed a synaptic 
incidence of 8.8% (Contant et al., 1996). Low levels of synaptic incidence at axonal 
varicosities suggest that ACh release may occur either at synaptic or asynaptic sites. The 
positioning of DA D5 receptors at these varicosities further suggests DA modulation of 
ACh release from these sites. A study combining VAChT (a marker that labels 
cholinergic axon terminals more intensely than ChAT) and the DA D5 receptor would 
provide a more thorough analysis of DA D5 receptor localization on cholinergic axons. 
Studies examining the precise functional role of these receptors on ACh release, however, 
have yet to be conducted. 
The DA D5 receptor has been investigated in a number of cognitive- and motor-
related disorders, including schizophrenia, Tourette's syndrome, antisocial personality 
disorder, attention-deficit hyperactivity disorder, and drug abuse (Barr et al., 1997; 
Vanyukov et al., 1998; Barr et al., 2000; Filip et al., 2000; Vanyukov et al., 2000; Muir et 
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al., 2001). The specific role of the DA D5 receptor, however, is not yet clear. One of the 
limitations of research focused on uncovering the precise function of the DA D5 receptor 
is the lack of specific DA D5 receptor subtype agonists or antagonists. Therefore, there is 
no direct evidence correlating the DA D5 receptor with a specific cellular function or 
behavioral effect. One means of inferring the role of DA D5 has been to investigate the 
role of D1-class agonists on striatal cholinergic neurons because of the preponderant 
localization of DA D5 (and not D1) on these neurons (Suzuki et al., 2001). Knockout 
animals have also recently been used to study the effects of DA D5 receptors (Centonze 
et al., 2003; Elliot et al., 2003); however, in combination with those studies, specific 
agonists or antagonists are required to more precisely investigate the role of the DA D5 
receptor subtype. 
Dopamine D1 and D5 receptors are receptor homologs, sharing the highest degree 
of homology within their transmembrane segments. However, these two receptor 
subtypes possess some structural and functional differences. For example, these two 
receptor subtypes differ by two amino acids in the C-terminal region of the third 
cytoplasmic loop (Charpentier et al., 1996). This structural difference is believed to be 
responsible for the differences in binding affinity observed between these two receptor 
subtypes (Sugamori et al., 1998). The DA D5 receptor has a binding affinity to DA that is 
10 times greater than the DA D1 receptor, as well as a more potent intracellular G-
protein-coupling mechanism (Grandy et al., 1991; Sunahara et al., 1991; Kimura et al., 
1995). Therefore, while the DA D5 receptor is classified functionally as a D1-class 
receptor, this receptor subtype possesses some structural and functional differences 
requiring further investigation. 
The cellular transduction mechanisms triggered by the activation of DA D1 and 
D5 receptors, in turn, will contribute to a wide range of cellular and behavioral outcomes. 
For example, it has recently been reported that the DA interacting protein calcyon 
facilitates DA D1 receptor release of intracellular Ca2+ through the involvement of an 
inositol 1,4,5-triphosphate-gated (InsP3) cascade (Bergson et al., 2003). Intracellular 
Ca2+ release in turn has been linked to plasticity and learning, more specifically LTP 
(Yeckel et al., 1999), and spine plasticity (Korkotian and Segal, 1999). It is further 
posited that the DA D5 receptor may be similarly involved given the 80% sequence 
similarity that it shares with the DA D1 receptor calcyon-binding motif. In general, an 
understanding of such DA signaling molecular mechanisms will have important clinical 
implications. For example, an increase in calcyon (100%) has been observed in the 
prefrontal cortex of schizophrenic patients (Koh et al., 2003). Additionally, Paspalas and 
Goldman-Rakic (2004) have recently provided ultrastructural evidence that DA D5 (but 
not D1 or D2) receptors are localized in the perisomatic plasma membrane of prefrontal 
cortical cells which form extrasynaptic microdomains with InsP3-gated calcium stores of 
subsurface cisterns and mitochondria. Such discrete receptor positioning may serve to 
translate extracellular DA signals into receptor-specific spatiotemporal downstream 
signaling similar to the one-to-one  spatiotemporal properties attained through chemical 
synapses. 
The present study provides supporting evidence that the DA D5 receptor subtype 
may serve as an important neuroanatomical substrate involved in mediating DA 
influences on ACh neurotransmission throughout the brain. Findings from this study in 
addition to future investigations of the functional role of the DA D5 receptor may reveal 
an important neural substrate for dopaminergic signaling that has been largely 
overlooked. In particular, it will become important to gain an understanding of the 
positioning of these receptors at specific sites on cholinergic neurons and other cell types 
and their relationship to synaptic and volume transmission influences. The cellular 
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positioning together with the high affinity properties of DA D5 receptors will define the 
precise circumstances in which these receptors are activated. The high affinity properties 
of the DA D5 receptor, for example, would favor DA signaling at low neurotransmitter 
levels and potentially long-range spillover or volume transmission influences. 
Furthermore, this receptor would be differentially responsive to changes in DA levels that 
occur as a result of behaviorally guided tonic versus phasic firing of mesencephalic DA 
neurons, as described for such a behavioral phenomenon as learning and such disorders 
as drug abuse and schizophrenia (Grace, 1991; Schultz, 2001; Phillips et al., 2003). 
In conclusion, an understanding of the localization of DA D5 receptors at defined 
sites on cholinergic cells and their relationship to functionally defined cellular 
microcircuits and intracellular transduction pathways will provide a greater 
understanding of the precise role that DA D5 receptors play in a variety of cognitive-, 
limbic-, and motor-related behaviors. These findings will also serve to guide the 
development of improved site-specific targeted pharmacotherapeutic strategies and 
cognitive-behavioral treatments for a variety of neuropsychiatric disorders. 
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Chapter 4: Localization of Dopamine D2 Receptors on Cholinergic 
Interneurons of the Dorsal Striatum and Nucleus Accumbens of the Rat 
4.1  Abstract 
Striatal cholinergic interneurons located in the dorsal striatum and nucleus 
accumbens are amenable to influences of the dopaminergic mesolimbic pathway, which 
is a pathway involved in reward and reinforcement and targeted by several drugs of 
abuse. Dopamine and acetylcholine neurotransmission and their interactions are essential 
to striatal function, and disruptions to these systems lead to a variety of clinical disorders. 
Dopamine regulates acetylcholine release through dopamine receptors that are localized 
directly on striatal cholinergic interneurons. The dopamine D2 receptor, which attenuates 
acetylcholine release, has been implicated in drug relapse and is targeted by therapeutic 
drugs that are used to treat a variety of neurological disorders including Tourette’s 
syndrome, Parkinson’s disease and schizophrenia. The present study tested the hypothesis 
that cholinergic interneurons in the dorsal striatum and nucleus accumbens express the 
dopamine D2 receptor. This study provides the first direct evidence for the localization of 
dopamine D2 receptors on striatal cholinergic interneurons of the rat brain using dual 
labeling immunocytochemistry procedures. Using light microscopy, dopamine D2 
receptors were localized on the cell somata and dendritic and axonal processes of striatal 
cholinergic interneurons in the dorsal striatum and nucleus accumbens of the rat brain. 
These findings provide a foundation for understanding the specific roles that cholinergic 
neuronal network systems and interacting dopaminergic signaling pathways play in 
striatal function and in a variety of clinical disorders including drug abuse and addiction. 
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4.2 Introduction 
This study focused on dopamine–acetylcholine interactions in the dorsal striatum 
and the nucleus accumbens of the rat brain. The dorsal striatum which integrates a variety 
of cortical and limbic information is involved primarily in the regulation of motor 
function. The nucleus accumbens (NAcc), which is a major area of the ventral striatum, 
has been an area of intensive investigation as central to the rewarding and locomotor 
effects of drugs of abuse and other naturally rewarding behaviors. The dopaminergic 
mesolimbic pathway, which originates in the ventral tegmental area (VTA) and provides 
extensive afferent projections to the dorsal striatum and NAcc, is targeted by several 
drugs of abuse including cocaine, amphetamine, heroin, morphine, nicotine and alcohol 
(Self and Nestler, 1995; Berke and Hyman, 2000). These dopaminergic projections 
maintain distinct topography within the subdivisions of the dorsal striatum, and the two 
major divisions of the NAcc, the shell and core (Gerfen et al., 1987; Heimer et al., 1991; 
Usuda et al., 1998). These subdivisions, therefore, have distinct structure, connectivity, 
and morphology and thus subserve separate reward and motor-related phenomena.  
This study focused on cholinergic interneurons of the dorsal striatum and NAcc, 
which are amenable to dopaminergic mesolimbic influences through the activation of 
dopamine (DA) receptors that are located directly on these neurons. Cholinergic 
interneurons are important neuronal integrators and modulators of striatal function and 
dysfunction. These neurons possess key receptors that are linked to molecular signaling 
pathways critical for plasticity (Calabresi et al., 2000). Striatal cholinergic interneurons 
also express long-term potentiation (LTP) (Suzuki et al., 2001) and play a unique role in 
reward mediated associative learning (Aosaki et al., 1994). Furthermore, these local 
circuit neurons have been demonstrated to exert powerful influences on medium spiny 
output neurons (MSNs) and thus on overall striatal signaling (Howe and Surmeier, 1995). 
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More specifically, cholinergic interneurons have been reported to modulate corticostriatal 
NMDA receptor signaling onto MSNs and the LTP that is expressed by these striatal 
output neurons (Calabresi et al., 2000; Alcantara et al., 2001).  
The effects of DA actions on cholinergic interneurons are mediated through two 
types of G-protein coupled receptors: D1-class (D1, D5) and D2-class (D2, D3, D4). The 
cellular processes associated with these receptor subtypes have been linked directly to 
neural plasticity and learning as well as drug-seeking behavior (Self et al., 1996; 
Watanabe and Kimura, 1998; Nicola et al., 2000; De Vries and Shippenberg, 2002). It 
has been shown that dopamine exerts mainly opponent action on D1- and D2-like 
dopamine receptors. Acetylcholine (ACh) release is increased by dopamine D1-like 
agonists (Consolo et al., 1999), while dopamine D2 receptor activation has been shown in 
both in vivo and in vitro studies to inhibit ACh release (Lehmann and Langer, 1983; 
Stoof et al., 1987; Bertorelli and Consolo, 1990; Damsma et al., 1990; Drukarch et al., 
1990). In addition to their opposing effects, however, synergistic effects can also occur 
through the co-activation of dopamine D1 and D2 receptors (LaHoste and Marshall, 
1993; Hu and White, 1994; Kashihara et al., 1999).  
The aim of the present study was to identify the distribution of dopamine D2 
receptors on cholinergic interneurons of the dorsal striatum and NAcc in the rat brain, 
using light microscopy with immunocytochemical dual labeling procedures. This study 
provides evidence of a neuroanatomical substrate for possible reward and motor mediated 
DA influences onto dorsal striatal and accumbal cholinergic neuronal network systems. 
The findings from this work should lead to a better understanding of cholinergic circuitry, 
specifically that involving DA signaling onto cholinergic neurons and the effects of 
acetylcholine neurotransmission on overall striatal function and dysfunction. (This study 
has been published: Alcantara et al., 2003). 
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4.3 Methods  
Experimental procedures conformed to National Institute of Health guidelines and 
were carried out under an institutionally reviewed and approved research protocol. 
4.3.1 Animals 
Twelve adult male Sprague–Dawley rats (Simonsen Labs) were used in this study. 
4.3.2 Tissue Preparation 
Animals were administered an overdose of sodium pentobarbital (Nembutal; 100 
mg/kg i.p.) and perfused transcardially with 60 ml of 0.1 M phosphate buffered saline 
(PBS), pH 7.4 followed by 200 ml of 4% paraformaldehyde/0.1% glutaraldehyde in PBS, 
pH 7.4. The brains were removed and post-fixed for 1 h in 4% paraformaldehyde in PBS. 
Vibratome sections were taken at a thickness of 70 µm, placed in 15% sucrose in PBS, 
and frozen in liquid nitrogen. Tissue sections were then thawed and processed for light 
microscopy utilizing single or dual labeling immunocytochemistry (ICC) procedures for 
dopamine D2 receptor and choline acetyltransferase (ChAT). 
4.3.3 Light Microscopy Immunocytochemistry 
D2/Vector SG and ChAT/DAB immunolabeling 
Light microscopy dual labeling immunocytochemical procedures were performed 
on free-floating, coronal tissue sections which were rinsed in 0.1 M PBS (3×10 min) and 
preincubated for 1 h in a PBS blocking solution containing 5% normal goat serum 
(NGS). Sections were then incubated simultaneously in a cocktail of both primary 
antibodies: rabbit dopamine D2 receptor polyclonal antibody (1:350; Chemicon) and 
mouse ChAT monoclonal antibody (1:1000; Chemicon) for 24 h at 4 °C. The preparation, 
characterization, and specificity of the dopamine D2 receptor antibody have been 
previously described (Bunzow et al., 1988; Farooqui et al., 1991; Brock et al., 1992; 
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Sakata et al., 1992). Sections were rinsed in PBS (4×5 min; and similarly rinsed after 
each step unless otherwise specified). The tissue was then incubated in secondary 
biotinylated donkey anti-mouse IgG antiserum (1:500; Jackson ImmunoResearch), 
diluted in 2% NGS-PBS for 2 h, and then incubated in an avidin–biotin peroxidase 
complex (ABC Vectastain Elite Kit; Vector) for 1 hr. ChAT-immunoreactivity (IR) was 
visualized with 0.05% 3,3′-diaminobenzidine tetrahydrochloride (DAB) and 0.01% H2O2 
in PBS which resulted in a brown reaction product. Sections were subsequently incubated 
in secondary biotinylated goat anti-rabbit IgG antiserum (1:200; Vector) diluted in 2% 
NGS-PBS for 1 h and then incubated in the ABC complex for 1 hr. Dopamine D2 
receptor immunoreactivity was visualized with the Vector SG substrate kit, resulting in a 
blue reaction product.  
In order to verify the specificity of the ChAT/DAB and D2/SG dual labeling 
procedures, all combinations of single labeled ChAT and dopamine D2 receptor 
visualized with either DAB or Vector SG were employed. Specific labeling for the 
respective antigens was observed in all of these procedures. Control sections for single 
and dual labeling procedures were processed identically with the exception that primary 
antibodies were omitted from the incubation solution. Single labeling was observed when 
one of the primary antibodies was omitted, and no staining was detected in the absence of 
both antibodies.  
4.4 Results 
Light microscopic dual immunolabeling: D2 (Vector SG) and ChAT (DAB) 
Cholinergic interneurons of the dorsal striatum and shell and core compartments 
of the nucleus accumbens were identified by ChAT-IR visualized by the brown DAB 
immunoreaction product. ChAT immunoreactive neurons displayed the morphological 
features characteristic of large aspiny cholinergic interneurons (Kemp and Powell, 1971; 
Phelps et al., 1985). The somas of these neurons were oval, elongated, or multipolar, with 
a 30–50-µm soma diameter from which several, infrequently branching dendrites 
emerged, extending up to a millimeter in length. Cholinergic interneurons of the dorsal 
striatum and nucleus accumbens were typically situated in clusters (see Fig. 4.1). The 
striatal neuropil contained an extensive arborization of immunolabeled cholinergic 
dendrites and axons.  
    
 
 
Figure 4.1 Cholinergic Interneuron of the striatum. Cholinergic interneurons located 
in the striatum of the rat brain were identified by immunocytochemical labeling 
procedures using an anti-ChAT antibody and DAB label. Cholinergic cell somata 
measured 30–50 microns in diameter and their neuronal processes measured up to a 




The areas examined for dopamine D2 receptor and ChAT dual-labeling were contiguous 
70 micron-thick coronal sections taken between 2.70 and 0.70 mm anterior to Bregma 
(Paxinos and Watson, 1998) (see Fig. 4.2). Dual-labeling procedures revealed intense 
dopamine D2 receptor immunolabeling on striatal cholinergic interneurons located 
throughout the rostro-caudal extent of the dorsal striatum and nucleus accumbens of the 
rat. Dopamine D2 receptor labeled cholinergic interneurons in the dorsal striatum are 
shown in Fig. 4.3. Strong dopamine D2 receptor-IR, indicated by the Vector SG blue 
label, appeared on the perikarya of the cholinergic neurons and on circumscribed regions 




Figure 4.2 Dorsal striatum and nucleus accumbens atlas plates. Coronal sections 
from the atlas of Paxinos and Watson (1998) illustrate the boundaries of the rostro-caudal 
extent of the dorsal striatum and nucleus accumbens (Bregma 2.70 mm, Bregma 0.70 
mm, A, C) that were investigated in this study. A representative midregion section 








Figure 4.3 Dopamine D2 receptor localization on cholinergic interneurons of the 
dorsal striatum (A) Dopamine D2 receptors were localized on cholinergic interneurons 
of the dorsal striatum. Cholinergic interneurons were identified by ChAT-
immunoreactivity visualized by the brown DAB label, whereas the dopamine D2 
receptor-IR was recognized by the blue SG label. The dopamine D2 receptor was also 
evident on non-cholinergic neurons, presumably medium spiny output neurons. The dual 
labeled neuron that is outlined by the box is shown at higher magnification in B. (B) A 
high magnification light micrograph demonstrates that dopamine D2 receptor-IR (blue-
SG label) was present in the cell soma and at circumscribed regions along the processes 
of a cholinergic interneuron (brown-DAB label) that was located in the dorsal striatum. 
Scale bars =35 µm. 
 
The cell somata and processes of cholinergic interneurons located in the NAcc 
also contained the dopamine D2 receptor (Fig. 4.4). Dopamine D2 receptor-IR also 
appeared on numerous medium-sized neurons in the dorsal striatum and NAcc. Such 
medium-sized neurons are presumably GABAergic projection neurons and perhaps other 
striatal interneurons. The number of striatal neurons expressing the dopamine D2 receptor 
was not analyzed quantitatively. However, qualitative analysis reveals that most 
cholinergic interneurons in the dorsal striatum and nucleus accumbens display dopamine 
D2 receptor-IR. The axons of dorsal striatal and accumbal cholinergic neurons also 
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contained the dopamine D2 receptor. Receptor localization on a cholinergic axon of the 




Figure 4.4 Dopamine D2 receptor localization on cholinergic interneurons of the 
nucleus accumbens. (A) Dopamine D2 receptor-IR (blue-SG label) was evident on 
ChAT-positive (brown-DAB label) cholinergic interneurons of the nucleus accumbens. 
ChAT-IR was present in the perikarya and processes of these neurons. Dual-labeled 
neurons were present in both the shell and core compartments of the nucleus accumbens. 
The dual labeled neuron that is outlined by the box is shown at higher magnification in B. 
(B) A high magnification light micrograph demonstrates dopamine D2 receptor-IR (blue-
SG label) in the cell soma and circumscribed regions of the processes of a cholinergic 
interneuron located in the shell compartment of the nucleus accumbens. Scale bars =35 





Figure 4.5. Dopamine D2 receptor localization on axons of the nucleus accumbens 
and dorsal striatum. The dopamine D2 receptor was present on cholinergic axons 
located in the dorsal and ventral striatum of the rat brain. Cholinergic axons were 
recognized by a brown DAB label as illustrated in an accumbal cholinergic axon 
illustrated in A. Dopamine D2 receptor-positive axons in the striatum were identified by 
the blue-SG label. An accumbal dopamine D2 receptor-IR axon is illustrated in B. 
Occasionally, the dopamine D2 receptor was observed on cholinergic axons located in 
the dorsal and ventral striatum. A dual labeled (ChAT/D2) axon of the nucleus 
accumbens is shown in C. The dopamine D2 receptor is identified as the blue-SG label 
(arrows) on the brown DAB labeled cholinergic axon. The neuronal processes possess 




The main finding of this study was the cellular localization of dopamine D2 
receptors on cholinergic interneurons of the dorsal striatum and NAcc of the rat brain. 
Dopamine D2 receptors are targeted by several therapeutic drugs used in the treatment of 
such striatal-related disorders as Tourette Syndrome, Parkinson’s disease, and 
schizophrenia. Additionally, dopamine D2 receptors play a critical role in relapse and 
drug seeking behavior associated with several drugs of abuse (Self et al., 1996; De Vries 
and Shippenberg, 2002). The involvement of the mesolimbic DA pathway in drug abuse 
has been well documented. More recently, we and others have reported the involvement 
of cholinergic interneurons of the dorsal striatum and the shell compartment of the NAcc, 
which are areas targeted by the mesolimbic DA pathway, following the administration of 
such drugs of abuse as cocaine and alcohol (Consolo et al., 1999; Mark et al., 1999; 
Berlanga et al., 2003; Herring et al., 2004). The localization of dopamine receptors on 
dorsal striatal and accumbal cholinergic interneurons should therefore provide a clearer 
understanding of the cellular mechanisms that underlie addiction and other striatal-related 
clinical disorders. Ultimately, such findings should lead to the development of improved 
site-specific targeted behavioral and pharmaceutical treatments for these disorders.  
 
The cellular localization of dopamine D2 receptors on cholinergic interneurons of 
the dorsal striatum and nucleus accumbens 
The present study revealed that dopamine D2 receptors were localized on the 
perikarya, dendrites, and axons of cholinergic interneurons in the dorsal striatum and 
nucleus accumbens of the rat. These data are in accordance with evidence that the 
dopamine D2 receptor mRNA is present in striatal cholinergic interneurons (Surmeier et 
al., 1993; Yan et al., 1997; Nicola et al., 2000) and with pharmacological evidence 
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suggesting a direct dopamine D2 receptor effect on cholinergic interneurons of the 
striatum (Gorell and Czarnecki, 1986). Specifically, dopamine D2 receptors attenuate the 
release of acetylcholine release (Lehmann and Langer, 1983; Stoof et al., 1987; Bertorelli 
and Consolo, 1990; Damsma et al., 1990; Drukarch et al., 1990) by reducing N-type 
Ca2+ currents via a membrane-delimited, Gi/o class G-protein pathway (Yan and 
Surmeier, 1997). Co-activation of the dopamine D1 and D2 receptors typically produce 
opposing effects. The D2 receptor inactivates the D1 receptor/cAMP/DARPP-32/PP1 
pathway by inhibiting cAMP or alternatively by activating PP-2B and dephosphorylating 
DARPP-32 (Greengard, 2001). The co-activation of the D1 and D2 receptors, however, 
can also produce synergistic effects (LaHoste and Marshall, 1993; Hu and White, 1994). 
The separate or combined effects of DA D1 and D2 receptors on cholinergic neurons can 
therefore result in a range of cellular and behavioral effects.  
Medium-sized neurons, presumably the GABAergic output neurons of the 
striatum, were also observed to express dopamine D2 receptors, which is consistent with 
previous reports (Yung et al., 1995). Interestingly, ultrastructural evidence has 
demonstrated that dopamine D2 receptors on MSNs are relatively more localized on 
dendrites of the MSNs in the dorsal striatum and more on the axons of these neurons in 
the NAcc (Delle Donne et al., 1997). The behavioral outcome of DA D2 receptor 
activation will ultimately depend on the precise cellular localization of the receptor. For 
example, GABA release from medium spiny neurons is inhibited through the activation 
of the dopamine D2 receptor. Attenuation of this GABAergic influence onto cholinergic 
neurons causes the facilitation of acetylcholine release. Alternatively, the activation of 
dopamine D2 receptors on cholinergic interneurons will attenuate the release of 
acetylcholine. Glutamatergic corticostriatal and dopaminergic striatal afferent fibers have 
also been reported to possess dopamine D2 receptors (Sesack et al., 1994; Wang and 
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Pickel, 2002). The effects of dopaminergic signaling in the striatum are therefore 
widespread due to the presence of dopamine receptors on the dendrites and axons of a 
variety of striatal neurons including cholinergic interneurons and on striatal axonal 
afferent pathways.  
 
Dopamine D2 receptor involvement in addiction and other striatal-related clinical 
disorders 
Treatments for a variety of clinical disorders have been developed which 
specifically target the dopamine D2-class receptors. Haloperidol and clozapine, which are 
used in the treatment of Tourette’s syndrome and schizophrenia, respectively, are 
dopamine D2 receptor antagonists. Alternatively, bromocriptine, which is used to treat 
Parkinson’s disease, is a dopamine D2 receptor agonist. Dopamine D2 receptors 
specifically play an important role in reinstated drug-seeking behaviors, whereas 
dopamine D1 receptors are more critical to drug-induced satiation and tolerance (Self et 
al., 1996). More specifically, dopamine D2 receptor family agonists have been shown to 
mimic the priming effects of cocaine in monkeys trained to self-administer the drug, 
whereas dopamine D1 receptor agonists did not reinstate the behavior (Khroyan et al., 
2000). In addition to the importance of DA D2 receptors in relapse and the reinstatement 
of drug-seeking behaviors, (Self et al., 1996; De Vries and Shippenberg, 2002), these 
receptors have also been reported to be up-regulated during early withdrawal (Sousa et 
al., 1999). These receptors and their respective cellular microcircuits may therefore prove 
to be critical target sites for drug treatment programs.  
Moreover, the dopamine D2 receptor activation on cholinergic interneurons may 
oppose the effects of DA D1 receptors or alternatively may play a unique role in 
potentiating the effects of ACh release through the synergistic effects of combined D1 
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and D2 activation (LaHoste and Marshall, 1993; Hu and White, 1994). Earlier in situ 
hybridization studies reported the presence of dopamine D1 and D2 receptor mRNAs on 
separate populations of striatal projection neurons (Gerfen et al., 1990; Gerfen et al., 
1995), however more recent findings report D1- and D2-receptor co-localization using 
immunocytochemical methods, (Surmeier et al., 1993; Gerfen and Keefe, 1994). Our data 
are in good agreement with previous in situ hybridization studies, which report D1 and 
D2 mRNA on cholinergic neurons (Nicola et al., 2000) as well as recent 
immunocytochemical work that found D1-class receptor localization on cholinergic 
neurons. Dopamine D1-class receptors, specifically the D5 receptor subtypes, which have 
an affinity for dopamine ten times higher than that of D1 receptors (Grandy et al., 1991), 
have recently been localized on striatal cholinergic interneurons of the nucleus 
accumbens and other brain areas (Rivera et al., 2002; Berlanga et al., 2005). Virtually all 
cholinergic interneurons in the dorsal striatum and NAcc express the D5 receptor. It is 
likely that the combined effects of D1/D5- and the D2-class receptors (opposing or 
synergistic), which we have localized on cholinergic interneurons in the present study, 
will depend on the specific pharmacological and behavioral stimuli and respective 
microcircuits that elicit their activation. As a result, the overall cellular and behavioral 
effects of a drug may differ depending on whether the drug is self-administered or 
administered passively, see for example, (Mark et al., 1999).  
 
Conclusions and implications for future studies 
In conclusion, DA–ACh interactions are critical for striatal function and pivotal to 
a variety of clinical disorders. Dopaminergic signaling occurs through the activation of 
D1- and D2-class receptors. The localization of these receptors has been reported on 
medium spiny output neurons as well as on striatal glutamatergic and dopaminergic 
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afferent projections. This study is the first to report the cellular localization of dopamine 
D2 receptors on cholinergic interneurons. The D1-class receptor subtype, D5, has also 
recently been reported to be localized on accumbal cholinergic interneurons. Of critical 
importance will be to co-localize D5 and D2 receptors on these cholinergic neurons since 
their potential synergistic effects may be critical to such behavioral phenomenon as 
learning (Calabresi et al., 1992). It will also be important to examine, in future studies, 
the effects of converging DA and glutamate inputs onto these cholinergic neurons since 
such convergence may underlie associative learning, which is posited to play an 
important role in addiction (Vanderschuren and Kalivas, 2000; Anagnostaras et al., 
2002).  
Our findings should provide a basis for future investigations designed to better 
understand the DA influence onto cholinergic neuronal circuitry of the dorsal striatum 
and nucleus accumbens. Such knowledge should contribute to our understanding of the 
underlying molecular basis of addiction and other clinical disorders. Focus on the 
cholinergic system and its interface with the DA mesolimbic pathway and glutamatergic 
limbic and prefronto-striatal pathways should identify microcircuits that should be 
targeted by pharmaceutical and behavioral treatment programs for addiction and a variety 




Chapter 5: Morphine- and Cocaine-Induced Synaptic Rewiring in the 
Nucleus Accumbens: Potential Neural Substrates Underlying Drug-
Induced Behavioral Changes  
5.1 Abstract  
Repeated use of psychostimulants and opiates can lead to such behavioral changes 
as motor sensitization, tolerance, psychosis and relapse. Many studies have attempted to 
identify molecular and cellular events responsible for such drug-induced behaviors, 
which can persist for years. Increasing evidence suggests that these behavioral changes 
may be mediated by persistent structural changes in the brain, such as changes in synapse 
number. A major site of synaptic contact is the dendritic spine (Harris and Kater, 1994). 
Previous studies have reported an increase in the density of spines on medium spiny 
neurons of the nucleus accumbens (NAcc) and pyramidal cells of the prefrontal cortex 
(PFC) following repeated injections of cocaine (Robinson and Kolb, 1999b), and a 
decrease in spine density following morphine injections (Robinson and Kolb, 1999a). In a 
more recent study, motor sensitization was associated with an increase in spine density in 
the core compartment of the NAcc of cocaine-sensitized animals (Li et al., 2004). 
Evidence of such morphological changes in the NAcc following long-term drug intake 
suggested that synaptic changes were also occurring. Therefore, the present study tested 
the hypotheses that the synapse per neuron ratio would increase in the NAcc shell and 
core of cocaine-treated rats and decrease in morphine treated animals, and that increases 
in the number of synapses per neuron in the NAcc core would be associated with animals 
exhibiting behavioral sensitization.  
Adult female Sprague-Dawley rats were given 20 days of repeated, intermittent 
injections of either 15 mg/kg cocaine or 10 mg/kg morphine. Animals were left 
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undisturbed for an additional 3 weeks to test for the persistence of structural changes. 
Electron microscopy and unbiased quantitative stereological analyses revealed an 
increase in the synapse per neuron ratio in the NAcc shell of cocaine-treated (49.1%) and 
morphine-treated (55.1%) rats, relative to controls. However, an increase in the synapse 
per neuron ratio in the NAcc core was found only in cocaine-sensitized animals (49.1%). 
More specifically, the increases found in both the shell and the core, were primarily due 
to an increase in the number of asymmetric (Gray’s Type I) synapses, suggesting 
plasticity in glutamatergic synapses. This study provides the first ultrastructural evidence 
of cocaine-induced synaptic changes, and identifies functionally distinct types of 
synapses that underlie cocaine-induced motor sensitization. 
5.2 Introduction  
Recent studies indicate that long-term use of drugs of abuse leads to 
neuroadaptations in the nucleus accumbens (NAcc) at the level of gene expression 
(Carlezon et al., 1998; Shaw-Lutchman et al., 2002) and at the level of cellular 
morphology (Robinson and Kolb, 1999a, b; Norrholm et al., 2003). Such changes 
presumably underlie long-lasting drug-induced behaviors observed during escalated drug 
intake and after prolonged abstinence from addictive substances (Chao and Nestler, 
2004).  
Long-term treatment with cocaine and morphine induce structural changes in the 
NAcc shell and medial PFC, two primary targets of the mesolimbic dopamine (DA) 
pathway. Golgi-Cox staining of output neurons in these brain areas reveals an increase in 
dendritic branching and spine density following repeated i.p. treatment with cocaine 
(Robinson and Kolb, 1999b; Norrholm et al., 2003) and a decrease in dendritic branching 
and spine density following repeated i.p. treatment with morphine (Robinson and Kolb, 
1999a). Furthermore, spine density changes in the NAcc core have recently been 
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correlated with the expression of behavioral sensitization (Li et al., 2004). Thus, the spine 
density changes detected by Robinson and colleagues may underlie the persistent 
behavioral changes observed even after drug cessation.  
At the behavioral level, sensitization and tolerance reportedly occur following 
repeated cocaine and morphine treatment. The expression of behavioral sensitization and 
tolerance varies depending on the drug dose and frequency of administration. In general, 
cocaine-sensitized rats exhibit enhanced exploratory behaviors such as sniffing, 
locomotor activity and rearing, as well as stereotyped sniffing and headbobbing minutes 
after drug administration (Wise, 1984; Guan et al., 1985; Zahniser et al., 1988; Steketee 
et al., 1992; O'Dell et al., 1996). Morphine-sensitized rats also demonstrate an enhanced 
locomotor response to repeated drug administration (Jeziorski and White, 1995; Cadoni 
and Di Chiara, 1999). Furthermore, prolonged treatment with morphine leads to the 
expression of a stereotyped chewing/gnawing behavior (Pollock and Kornetsky, 1989; 
Kornetsky, 2004). Alternatively, behavioral tolerance in cocaine-treated rats is not as 
readily detectable as in morphine-treated animals. Continuous administration of cocaine 
(5 to 40 mg/kg per day) over the course of 14 days has been shown to induce behavioral 
tolerance (King et al., 1999), whereas behavioral tolerance to the analgesic effects of 
morphine, if administered continuously (16.8 to 36 i.v. mg/kg per day), can develop 
within 8 to 12 hours (Ouellet and Pollack, 1995) or after 7-10 days if administered 10 
mg/kg once a day intraperitoneally (Yamamoto et al., 1988). Examination of specific 
microcircuits and drug-induced synaptic changes underlying these drug-induced 
behaviors require further examination.   
The structural alterations in reward and motor related brain regions that 
accompany the observed behavioral changes resulting from repeated treatment with 
cocaine and morphine suggest that synaptic reorganization may also be occurring. Such 
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synaptic changes have not been previously examined. The spine density changes 
observed using the Golgi-Cox staining procedure and the assumption that spine density 
changes extend to synaptic changes has long been open to criticism. For example, this 
staining technique only stains a small percentage (approximately 1-5%) of the total 
neurons (Pasternak and Woolsey, 1975). Therefore, synaptic changes associated with 
long-term drug treatment must be confirmed through direct examination at the electron 
microscopic level. Evidence of changes in synapse number will require future studies at 
the electron microscopic level to provide insight into the specific types of synapses that 
are changing. The present study tested the hypothesis that the number of synapses per 
neuron increase in the NAcc shell and core of cocaine and morphine treated rats.  
5.3 Methods 
All experimental manipulations were carried out during the light portion of the 
cycle. Animals were handled for 15 minutes twice daily and vaginal smears were 
obtained once daily for 7 days prior to any experimental manipulation. Experimental 
procedures conformed to National Institutes of Health guidelines and were carried out 
under an institutionally reviewed and approved research protocol. 
5.3.1 Animals 
Twenty-four adult female Sprague-Dawley rats weighing 250-300g, provided by 
the Animal Resources Center at the University of Texas at Austin, were used in this 
study. Rats were individually housed in clear plastic hanging cages (45 x 23.5 x 20.75 
cm) in an animal colony room with ad libitum access to food and water, under a 12 hour 
light-dark cycle (lights on at 0700 hours). Daily vaginal smears were collected prior to 
drug injections at approximately the same time every day during the 4 week drug 
treatment. Two animals had to be removed from the study. One received the wrong drug 
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injection on the last testing day, and another developed a growth near the site of injection 
after the first day of testing. All experimental manipulations were carried out during the 
light portion of the cycle. Animals were handled for 15 minutes twice daily and vaginal 
smears were obtained once daily for 7 days prior to any experimental manipulation. 
Experimental procedures conformed to National Institutes of Health guidelines and were 
carried out under an institutionally reviewed and approved research protocol.  
5.3.2 Drug Administration 
Rats were randomly divided into 3 groups, Cocaine (n=7), Morphine (n=7), and 
Saline (n=8). Morphine sulfate (10 mg/kg) and cocaine hydrochloride (15 mg/kg) were 
dissolved in 0.9% saline and injected i.p. at 1 mL/kg of body weight. All doses are 
expressed as the weight of the salt. Drug injections were administered in the testing room 
and animals were immediately placed into the test cage following the injection. The test 
cage was a clear plastic cage (45 x 23.5 x 20.75 cm). Grid lines were made on the outside 
of the bottom of the cage dividing the cage into 6 quadrants.  The lines were used to score 
line crosses following drug administration. On the first day of drug testing, rats were 
removed from their home cage and were given an i.p. injection of 15 mg/kg cocaine 
hydrochloride, 10 mg/kg morphine sulfate, or 1 mL/kg of 0.9 % saline followed by 
confinement to the test cage. Motor activity in the test cage was recorded with a video 
camera for 60 minutes immediately following the injection. Animals were then returned 
to their home cage following the testing session. These procedures were repeated 5 days a 
week, followed by 2 consecutive drug-free days over a total of 4 weeks. After the last 
testing day, animals were left undisturbed for an additional 21 days before their brains 
were removed. 
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5.3.3 Behavioral Analysis 
Immediately following the drug injection, animals were placed into the testing 
cage and their behavior was recorded for 60 minutes. Video tapes were coded and later 
viewed by observers blind to group assignment. Behaviors quantified from the video 
footage included: line crosses, rearing, headbobbing, sniffing, grooming, immobility, 
chewing/gnawing, and sleeping.  Line crosses were counted when both forepaws crossed 
a line as the rat moved in the forward direction. Rearing activity was measured when the 
rat stood on its hind legs, either supported by the cage or unsupported. Headbobs were 
counted as head movements in the vertical direction (up to down), while stationary with 
all paws on the ground. Sniffing was timed while the rat was in a rearing position 
(sniffing up) or a standing position with all four paws on the ground (sniffing down). 
Grooming behavior was timed for only grooming of the face and head. Immobility was 
characterized by freezing behavior in the absence of head movement. Chewing/gnawing 
behavior was recorded when animals chewed either their claws (forepaws or hind paws) 
or the walls of the cage. Sleeping behavior was timed when rats were immobile with their 
eyes closed or when they tucked their heads under the trunk of their body, sometimes 
with their tail wrapped around them. Grooming, sniffing, immobility, chewing/gnawing 
and sleeping were recorded measured in the number of bouts and in the number of 
seconds. 
5.3.4 Tissue Preparation 
Animals were administered an overdose of sodium pentobarbital (Nembutal; 100 
mg/kg i.p.) and perfused transcardially with 60 ml of 0.1 M phosphate buffered saline 
(PBS), pH 7.4 followed by 200 ml of 4% paraformaldehyde/0.6% glutaraldehyde in PBS, 
pH 7.4. The brains were removed and post-fixed for 2 hours in 4% 
paraformaldehyde/0.6% glutaraldehyde in PBS. Coronal sections were taken at a 
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thickness of 100 µm on a vibratome. Free-floating sections were then processed for 
electron microscopy. All efforts were made to minimize animal suffering and the number 
of animals used. 
5.3.5 Electron Microscopy 
The tissue sections were rinsed in 0.1M phosphate buffer (PB) and incubated in 
1% osmium tetroxide in PBS for 1 hour. Tissue is dehydrated through a graded series of 
alcohol concentrations, propylene oxide, and a 50:50 mixture of propylene oxide and 
Embed-812 (Electron Microscopy Sciences). The tissue sections were placed on an open 
rotator overnight in 100% Embed-812 (medium hardness). The following day, specimens 
were placed in fresh epon and flat embedded between two sheets of ACLAR film 
(Electron Microscopy Sciences) and cured at 60°C for 48 hours.  Polymerized and 
osmicated tissue sections were inspected under a light microscope to locate the target 
region using reliable neuroanatomical landmarks corresponding to the Paxinos and 
Watson Stereotaxic Coordinates for the Rat Brain (1995). The target region was excised 
and then glued to an epon rod, one from the NAcc shell and one from the NAcc core. A 
glass knife was used to trim the specimen to a size of 0.5 by 0.5 mm on an 
ultramicrotome (Leica Ultracut UCT). One block of tissue was used for each animal for 
each brain region. Ten semithin sections (~500 nm-thick) and four ultrathin sections (~70 
nm-thick) were cut on the ultramicrotome using a diamond knife (Ted Pella) from the 
same block of tissue from each animal. Every other semithin section was dried onto a 
superfrosted glass slide (5 sections), at which point a ribbon of 4 serial ultrathin sections 
was collected onto a formvar-coated slot grid. This process was repeated four times until 
a total of 20 semithin sections were collected onto a glass slide and 16 ultrathin sections 
were collected onto slot grids (4 slot grids total). Semithin sections were stained with 
toluidine blue and ultrathin sections were counterstained with 2% uranyl acetate 
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(aqueous) and examined and photographed using a Philips EM208 transmission electron 
microscope (TEM) (FEI Company) at 80kv.  Images, 1 Mb in size, were collected with 
an AMT Advantage HT camera. 
5.3.6 Electron Microscopic Data Analysis 
All photographs were taken at a magnification of 18000X. Images were stored 
and analyzed by one observer blind to group assignment. The observer counted all 
synapses in the shell and core compartments of the NAcc. Synapses were categorized as 
asymmetric, symmetric or undefined. Asymmetric synapses were identified by the 
presence of at least three round synaptic vesicles in the presynaptic terminal and a 
postsynaptic density, and symmetric synapses were identified by the presence of three 
flat (i.e. pleomorphic) vesicles and two closely apposing membranes. The postsynaptic 
target was identified for each synapse quantified in the study whenever possible. 
5.3.7 Stereological Methods 
The present study examined changes in the synapse per neuron ratio because this 
ratio has been shown to more accurately reflect changes in synapse number when neuron 
number is stable (Anker and Cragg, 1974). Furthermore, tissue shrinkage effects 
contributed equally to synapse density and neuronal density because measurements of 
neuronal and synaptic density are obtained from the same epon-embedded samples. An 
unbiased stereological estimation of the total number of synapses called the physical 
disector method was used to calculate neuronal density and synapse density, which 
involves comparing two serial sections (Gundersen et al., 1988). The first section was 
called the reference section and the second was the look-up section. When the object of 






Ten 500 nm-thick sections, described above, were used for neuron density 
analysis. Each semithin section was stained with toluidine blue, and cells were identified 
at the light level using a 40X lens on a computer assisted- light microscope. The physical 
disector method was used to calculate neuronal density, which involves comparing two 
serial sections. Within an unbiased counting frame of a known area (Aframe), the number 
of nuclei that were present in the reference section and not in the look-up section was 
counted (Q
-
neuron). Next, the disector volume of tissue (Vdis) is calculated using the 
following formula: 
    Vdis = Aframe x H     (i) 
 
where H is section thickness (1 µm) multiplied by the number of sections. The neuronal 
density, Nνneuron, was then determined by dividing the number of cells counted by the 




neuron/ Vdis (using semithin sections)   (ii) 
Synapse Density 
The ultrathin sections collected on formvar-covered copper slot grids were stained 
with 2% aqueous uranyl acetate before viewed under the TEM. Twenty micrographs 
were taken from two adjacent sections (~ 70 um thick) in the same position for a total of 
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40 micrographs per animal (twenty disector pairs), using one slot grid. The physical 
disector method was again used to calculate the synapse density, for which the number of 
synapses present in the reference section and not the look-up section were counted (Q
-
synapse). The total number of synapses within an unbiased counting frame of a known area 
(Aframe) was counted. Again, the disector volume of tissue (Vdis) is calculated using 
formula (i) from above, where H is section thickness (70 nm) multiplied by the number of 




synapse/ Vdis (using ultrathin sections) (iii) 
 
The number of synapses per neuron was determined by dividing the density of synapses 
per cubic millimeter by the neuronal density per cubic millimeter, as shown below: 
 
Nνneuron/ Nνsynapse (synapse to neuron ratio)  (iv) 
 
Section thickness of ultrathin sections was verified using “Small-Fold’s” 
technique (Weibel, 1979). For this calculation an image of a small fold (as compared to a 
useless fold as described by Weibel, 1979) is captured from an ultrathin section and the 
width of the fold can be estimated using the image scale bar. The following formula is 
then used: 
    2t = ℓ     (v) 
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where ℓ is the width of the small fold (using the scale bar) and t is the estimated thickness 
of the ultrathin section. 
5.3.8 Statistical Analysis 
The statistical analyses of behavioral and anatomical data were designed to test 
whether 1) rats show behavioral sensitization or tolerance to repeated drug treatment by 
comparing drug effect on day 1 to day 20 and 2) whether accompanying changes in the 
synapse per neuron ratio in the NAcc shell and core are significantly different in the 
drug-treated animals relative to control animals. Statistical analyses of behavioral data 
were performed using SPSS (SPSS, Inc.) repeated-measures analysis of variance 
(ANOVAs) for the effects of Groups, Days, and Group by Day interaction followed by 
pairwise comparisons using Bonferroni’s correction. Significant changes in the synapse 
per neuron ratio were determined by a one-way ANOVA followed by pairwise 
comparisons using Bonferroni’s correction. Significance level was set at p < .05. 
5.4 Results 
Behavioral Analyses of Non-Stereotypic Behaviors. As expected, cocaine-treated 
animals showed significantly more locomotor activity (line crosses and rearing) relative 
to control animals both on days 1 and 20 (Fig. 5.1A, B). A significant decrease in the 
total number of line crosses (Fig. 5.1A) and rears (Fig. 5.1B) was observed in cocaine-
treated animals by day 20. In contrast to cocaine, morphine administration on day 1 did 
not produce significant increases in locomotor activity relative to controls (Fig. 5.1A, B). 
Instead, morphine administration on day 1 produced motor inhibition (opiate catalepsy), 
reported here as immobility (Fig. 5.1C). Furthermore this drug-induced immobility was 





Figure 5.1. Non-stereotypic behaviors.
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treatment and day. (** indicates statistic
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Behavioral Analyses of Stereotypic Behaviors. A significant increase in the 
average number of stereotypic headbobs (Fig, 5.2A) and stereotypic sniffing (Fig. 5.2B), 
two reliable measures of cocaine-induced motor sensitization, was found in cocaine-
treated animals by day 20 relative to controls. Morphine-treated rats did not exhibit 
significant behavioral levels of stereotypic headbobbing; however, a pronounced 
morphine-induced stereotypic chewing/gnawing behavior was evident on day 20 (Fig. 





Figure 5.2. Stereotypic behaviors. The average (±SEM) number of headbobs 
(A) seconds spent sniffing (B) and seconds spent chewing/gnawing during the 1-
hour testing session (C), as a function of treatment and day. (** indicates 
statistical significance (p < .05) relative to control group and day 1; * indicates 
statistical significance (p < .05) relative to day 1). 
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Behavioral Analyses of Sleeping and Grooming Behaviors. Analysis of sleeping 
behavior revealed that control animals spend significantly more time sleeping on day 20 
relative to the first day of testing (Fig. 5.3). Drug-treated animals did not exhibit sleeping 
behavior during the 1 hour testing session. Therefore, all behavioral measures were 
adjusted for sleeping behavior observed in the control animals and re-evaluated (data not 
shown). All statistically significant behaviors reported above, remained significant. 
Additionally, when grooming behavior was adjusted for the time animals were asleep on 
day 20, instead of the total 60 minute video, a significant increase in grooming bout 
duration (i.e. the number of seconds spent grooming per bout) (Fig. 5.4A) and the total 





Figure 5.3. Sleeping behavior. The average (±SEM) time (seconds) observed for 
sleeping behavior, as a function of treatment and day. (* indicates statistical 
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reflects a change in the number of synapses. Specifically, there was a significant increase 
in the number of asymmetric synapses onto cells in the NAcc shell in cocaine-treated 
animals (62.2%) and morphine-treated animals (64.2%) (Fig. 5.5B). A subsequent 
correlation analysis was used to determine whether a direct correlation existed between 
the degree of sensitization (calculated as the difference between the times spent 
chewing/gnawing on the first and last day of drug treatment) and the number of 
asymmetric synapses quantified in this brain region. This analysis revealed that a direct 
negative correlation (R2 = 0.7332) existed between the degree of sensitization and the 
number of asymmetric synapses per neuron quantified from the NAcc shell of morphine-
treated animals (Fig. 5.6). Cocaine-treated animals did not show a direct correlation 
between synapse number in the NAcc shell and degree of sensitization using either of the 
stereotypic behaviors where evidence of sensitization was found. 
 
 
Shell: Asymmetric SynapsesShell: Total Synapses
 
Figure 5.5. Asymmetric synaptic quantification in the NAcc shell. The average 
(±SEM) number of total synapses (A) and asymmetric synapses (B), as a function of 
treatment in the NAcc shell. (* indicates statistical significance (p < .05) relative to 
control group). 
 
Synaptic Quantification NAcc Core. A significant increase in the total number of 
synapses per neuron was also found in the NAcc core of cocaine-treated animals (49%, p 
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= .013), but not morphine-treated animals, relative to controls (Fig. 5.7A). Again, a stable 
neuron density (cocaine = 208647 ± 15641.765 neurons per mm3; morphine = 209167 ± 
15641.765 neurons per mm3; control = 203962.13 ± 14631.531 neurons per mm3) reveals 
that this effect is driven by a change in synapse number. In the NAcc core, the number of 
asymmetric (excitatory) synapses increased by 52.5% (p = .022) relative to the control 
group (Fig. 5.7B). Again, a correlation analysis was used to determine whether a direct 
correlation existed between the degree of sensitization and the number of asymmetric 
synapses quantified in the NAcc core. This analysis revealed a positive correlation (R2 = 
0.7141) between the degree of sensitization of morphine-treated animals and the number 
of asymmetric synapses per neuron for the NAcc core (Fig 5.8). No such correlation was 
found in the NAcc core of cocaine-sensitized animals (data not shown). 
The percentage of asymmetric synapses made onto dendritic shafts (Fig. 5.9) and 
synapses made onto dendritic spines (Fig. 5.10) are reported in Table 5.1, as well as 
symmetric (inhibitory) synapses (Fig. 5.10), even though no conclusions were drawn 
from this category of synapses due to the limitations of the sampling strategy, which 
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Figure 5.6. Time spent chewing versus the number of asymmetric synapses 
per neuron in the NAcc shell of morphine-sensitized animals. A correlation 
analysis suggests a direct negative correlation (R2 = 0.7332) between the number 
of asymmetric synapses per neuron in the NAcc shell and the degree of 
sensitization (the difference in the time spent chewing between the last and first 
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Figure 5.7. Asymmetric synaptic quantification in the NAcc core. The average 
(±SEM) number of total synapses (A) and asymmetric synapses (B), as a function of 
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Figure 5.8. Time spent chewing versus the number of asymmetric synapses 
per neuron in the NAcc core of morphine-sensitized animals. A correlation 
analysis suggests a direct positive correlation (R2 = 0.7141) between the number 
of asymmetric synapses per neuron in the NAcc core and the degree of 
sensitization (the difference in the time spent chewing between the last and first 




Figure 5.9. Asymmetric synapse onto a dendritic shaft in the NAcc shell. Electron 
micrograph (18,000X) taken of an asymmetric synapse onto a dendritic shaft within the 
NAcc shell of a morphine-treated rat (Scale bar = 500 nm). (* indicates asymmetric axon 




Figure 5.10. Asymmetric and symmetric synapse onto a dendrite in the NAcc core. 
Electron micrographs (18,000X) taken of an asymmetric synapse onto a dendritic spine 
(asterisk) of a cocaine-treated rat (A) and dendritic shaft (thin arrow) of a control rat (B) 
within the NAcc core. A symmetric synapse (wide arrow) also appears in B making 
contact with the dendritic shaft (Scale bars = 500 nm).  
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Table 5.1. Percentage of Asymmetric and Symmetric Synapses onto Dendritic 
Spines and Dendritic Shafts in the Nucleus Accumbens Shell and Core. (The values 
listed reflect the total group means and standard errors for each condition (Control, 
Cocaine, Morphine), the percent of total synapses categorized as asymmetric and 
symmetric that made contact with either dendritic spines or dendritic shafts). * indicates 




The present study showed that 1) rats chronically administered cocaine or 
morphine (4 weeks) exhibit behavioral sensitization, and that following 3 weeks of drug 
abstinence, synaptic reorganization is observed in the NAcc shell, evident by an increase 
in the number of synapses per neuron, 2) these synaptic changes in the NAcc shell of 
drug-treated animals are driven by alterations in the number of asymmetric, presumably 
glutamatergic excitatory, synapses and 3) only cocaine-sensitized animals showed 
synaptic rewiring of asymmetric synapses in the NAcc core.  
In the present study, a categorical shift (i.e. locomotor to stereotyped) in the 
expression of cocaine-induced behaviors was observed between the first and last days of 
drug administration. Behavioral sensitization to cocaine was observed through the 
analysis of drug-induced stereotyped behaviors, including headbobbing and sniffing, but 
not the locomotor activating effects of cocaine, such as line crossing and rearing. Such 
changes in drug-induced behaviors over time have been previously described as the U-
shaped function (Fig. 5.11) relating psychostimulant dose to performance (Lyon and 
Robbins 1975; Dews and Wenger 1977). This theory describes a shift in the expression of 
drug-induced motor behaviors as drug dose varies. For example, both low and high doses 
of cocaine increase the behavioral motor response in a rat, but the low dose induces more 
line crosses while the high dose induces more stereotypic headbobbing. Thus, this shift is 
characterized by the disappearance of exploratory behaviors and replaced by the 
emergence of repetitive, purposeless stereotypic behaviors. Additionally, the design of 
the testing apparatus can influence the behaviors expressed by animals. For instance, 
Robinson and Kolb (1999b) placed a box insert in the middle of the test cage to create a 
walkway along the perimeter of the testing apparatus for the rats to move around 
following drug treatment. As such, sensitization was found through analysis of locomotor 
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activity, comparing the first and last day of drug treatment. The expression of 
sensitization in the present study found through analysis of stereotypic behaviors may 
have been influenced by the design of the testing apparatus which allowed for the 
expression of both locomotor and stereotypic behaviors. Previous studies have implicated 
NMDA receptors in the induction of cocaine sensitization because blockade of this 
receptor, using MK-801, during pretreatment with cocaine prevents the induction of 
behavioral sensitization (Wolf and Jeziorski, 1993). Moreover, application of this NMDA 
receptor antagonist also prevents certain molecular neuroadaptations associated with 
cocaine sensitization, such as DA autoreceptor subsensitivity and DA D1 receptor 




Figure 5.11 The inverted U-shaped model. These graphs depict the shift in behavioral 
response as dose varies. (A) Normal function applies to the increase in line crosses and 
exploratory behaviors observed with low doses of cocaine and the disappearance of these 
behaviors at higher cocaine doses. (B) Dysfunction applies to the emergence of 
stereotypic behaviors (repetitive, purposeless behaviors) that increase as drug dose 
increases. This figure was adapted from (Davis and Svendsgaard, 1990).  
 
Morphine administration, under this particular drug regimen, produced both 
motor sensitization (oral stereotypy) and motor tolerance (opiate catalepsy). Morphine-
induced stereotyped chewing/gnawing behavior has received little attention (Pollock and 
Kornetsky, 1989; Di Chiara, 1999), thus the neurochemical mechanisms underlying 
morphine-induced oral stereotypy are not yet clear. Fluoxetine, MK-801 and SCH23390 
all block the expression of this behavior, and only pretreatment with MK-801, an NMDA 
receptor antagonist, blocked the development of sensitization to this oral stereotypy 
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(Livezey et al., 1995; Wennemer and Kornetsky, 1999), thus, indicating an important role 
for glutamate in the development of this particular type of morphine-induced 
sensitization.  
Morphine-induced motor tolerance, as measured by morphine-induced catalepsy, 
has been reported in only a few studies to date (Hand and Franklin, 1985). The exact 
mechanism underlying opiate-induced catalepsy is not known, although it can be 
significantly prevented or reversed by phenytoin and naloxone (Cookson and Mann, 
1980). Morphine-induced immobility proved to be a reliable measure of motor tolerance 
in this study. This finding may be useful for future opiate tolerance studies, not 
necessarily interested in the analgesic effects of morphine, because it does not require a 
separate testing apparatus or added stressors (i.e. submersion of the tail in hot water) as is 
the case for the more commonly used tail-flick test.  
Both cocaine and morphine administration produced increases in the number of 
asymmetric synapses in the NAcc shell. First, this neuroadaptive effect shared by both 
drugs is in accordance with evidence surrounding the function of the NAcc shell, which 
is believed to be more responsive to reward signals because of its dense innervation by 
the limbic system. This hypothesis is further supported by the observation that DA 
release in the NAcc shell does not undergo habituation following repeated administration 
of drug-rewards, which is the case with non-drug rewards, such as caffeine (Di Chiara, 
1999). Thus, the synaptic changes observed in the NAcc shell reported in this study may 
be a result of a common reward-mechanism utilized by both drugs. Secondly, at the 
microcircuit level, an increase in the number of asymmetric synapses (presumably 
glutamatergic) in the NAcc shell suggests that projections from the PFC, amygdala, 
hippocampus, or thalamus may be occurring. The increase in the number of synapses per 
neuron in the NAcc shell is consistent with the increase in spine density reported by 
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Robinson and Kolb (1999b) in a cocaine study using a similar drug regimen. In the 
present study, analysis of the percentage of asymmetric synapses onto a specific 
postsynaptic target in the shell of cocaine-treated animals did not reveal any specific 
trends (i.e. synapse onto dendritic spine vs. synapse onto dendritic shaft) relative to 
controls. Thus, a more specific analysis is needed to determine the source and target of 
the synaptic changes associated with chronic cocaine treatment.  
In morphine-treated animals, an overall increase in the number of asymmetric 
synapses per neuron in the NAcc shell occurs despite the reduction in spine density as 
noted by Robinson and Kolb (1999a). Dendritic spine density is unaltered in the NAcc 
core following repeated morphine administration (Spiga et al., 2005), which is consistent 
with the findings of the present study. Interestingly, a trend towards an increase in the 
number of asymmetric synapses onto the dendritic shaft (versus a dendritic spine) 
suggested that this category of synapse may be more prevalent in this brain region. This 
trend is worth noting because this evidence suggests that 1) the decrease in spine density 
may not result in the loss of synaptic connections, rather it could be that the synapses 
retain contact with the target cell and the functional differences between synapses onto 
the dendritic shaft versus spine head and the differences in their effects on membrane 
excitability become important for this structural change and drug-induced behaviors. 
However, there is not enough information in this study to support this theory, and would 
have to be directly examined in a future study. 
Cocaine-sensitized rats revealed increases in the number of asymmetric synapses 
in the NAcc core. This finding agrees with previous studies depicting the NAcc core as a 
structure integrating motor with behavior. For example, cocaine-induced structural 
changes have been shown to occur in the NAcc core in animals expressing behavioral 
sensitization (Li et al., 2004), and lesions of the NAcc core severely impair cocaine-
 122
seeking behavior (Ito et al., 2004). In addition, the increase in the number of excitatory 
synapses in this brain region supports the idea of strong glutamatergic involvement in the 
mechanisms underlying behavioral sensitization to cocaine. Finally, the synaptic changes 
in the NAcc core were specific to the cocaine-sensitized, but not morphine-sensitized 
animals. Pharmacological and electrophysiological studies examining the effects of 
cocaine on behavioral sensitization consistently show involvement of the PFC. For 
instance, cocaine increases extracellular glutamate levels in the NAcc (Smith et al., 
1995), but morphine inhibits its release (Sepulveda et al., 1998). Similarly, repeated 
electrical stimulation of the PFC produces behavioral sensitization (Schenk and Snow, 
1994), whereas lesions of the PFC block the development of this behavior (Tzschentke 
and Schmidt, 1998). A separate analysis is necessary to determine whether the changes in 
the number of asymmetric synapses per neuron are in fact occurring within glutamatergic 
microcircuits associated with the PFC, because other glutamatergic projections to the 
NAcc arise from the amygdala, hippocampus and thalamus. Such changes in synaptic 
connectivity presumably occur as a consequence of repeated drug treatment and persist 
even after drug administration ceases; however such a conclusion requires a subsequent 
time course study in which synaptic changes are measured immediately following drug 
cessation and after an extended period of abstinence. 
A correlation analysis comparing the degree of sensitization (comparing first and 
last day of drug treatment) of morphine-treated animals and the number of asymmetric 
synapses per neuron in both the shell and core compartments of the NAcc revealed a 
marginally strong negative correlation (R2 = 0.7332) in the NAcc shell, and interestingly, 
a positive correlation (R2 = 0.7141) in the NAcc core. Reciprocal changes for the NAcc 
shell and core have been previously reported in morphine-sensitized animals (Cadoni and 
Di Chiara, 1999). Although Cadoni and Di Chiara (1999) report reciprocal changes in 
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DA responsivity of the NAcc shell and core, because of the well-established convergence 
of DA and glutamate onto MSNs (Sesack and Pickel, 1992; Kotter, 1994), the present 
findings may be a neuroadaptive change in response to the change in DA as a result of 
repeated morphine administration. This would have to be examined directly in a future 
study, likely with a higher number of animals in each group to detect a stronger 
correlation if one exists. 
The behavioral effects of repeated cocaine and morphine treatment in the present 
study produced sensitization in markedly different stereotypic behaviors, for example 
headbobbing and stereotypic sniffing (cocaine) versus chewing gnawing (morphine). 
These findings suggest that psychostimulants and opiates engage different neuronal 
mechanisms in behavioral sensitization, and such findings have been reported in a 
previous cross-sensitization study examining stereotypic behaviors exhibited by 
morphine-sensitized animals that receive a challenge injection of cocaine (Cadoni and Di 
Chiara, 1999). Moreover, results from the correlation analysis in the present study 
revealed two marginal correlations in morphine-sensitized animals. These correlations 
were opposite in direction (negative correlation in the shell and positive correlation in the 
core) between the number of asymmetric synapses quantified in the NAcc shell and core 
and the degree of sensitization. Evidence from the correlation analysis, although only 
marginal, suggests reciprocal functions of the shell and core compartments of the NAcc 
in morphine sensitization, which has been previously suggested. Reciprocal changes in 
DA neurotransmission in the shell and core compartments of the NAcc has been 
previously reported, where DA levels were shown to decrease in the shell and increase in 
the core following repeated morphine treatment (Cadoni and Di Chiara, 1999). Thus, the 
decrease in the number of asymmetric, possibly glutamatergic, synapses in the shell and 
increase in the core reported in the present study may be a consequence of changes in DA 
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release, given the convergence of dopaminergic and glutamatergic terminals on MSNs of 
the NAcc (Sesack and Pickel, 1992). Furthermore, no correlation was found in either 
brain region with cocaine-sensitized animals, further supporting the notion that different 
mechanisms underlie behavioral sensitization to cocaine and morphine. Additional cross-
sensitization studies are needed in order to further differentiate the long-term behavioral 
sensitizing effects, and the synaptic neuroadaptations accompanying these persistent 
behavioral changes, of different drug classes, such as psychostimulants and opiates. 
In conclusion, the present study reveals that long-term treatment with cocaine or 
morphine induces synaptic reorganization by increasing the number of excitatory 
synapses in the NAcc shell, and that similar changes in connectivity are observed in the 
NAcc core in cocaine-sensitized animals. To determine whether the neuroadaptive 
synaptic changes in the NAcc, reported in the present study, are causally-related to the 
observed behavioral changes, subsequent studies are needed. For example, additional 
studies aimed at abolishing behavioral sensitization through the blockade of drug-induced 
spine density changes, for example with the use of roscovitine, which has been shown to 
prevent cocaine-induced spine proliferation, could be conducted. Moreover, an 
examination of the contribution of local circuit neurons and specific brain regions 
projecting the NAcc that may be contributing to the increase in the synapse per neuron 
ratio also requires future analysis. The present study identifies a specific neuroadaptive 
change, synaptic plasticity, associated with long-term drug use. Such changes in synaptic 
connectivity found within the NAcc, a primary target of the mesolimbic DA pathway and 
drugs of abuse, are the first evidence of persistent neuroadaptive changes that could 
potentially underlie behavioral sensitization and other drug-related behaviors. Together 
these data suggest an important role for glutamate neurotransmission in the maintenance 
of long-term neuroadaptive changes and persistent behavioral changes observed during 
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drug abstinence. Furthermore, these findings offer new targets, such as specific cell types 
or synaptic circuits for future pharmacological and behavioral therapies for the 
prevention and treatment of drug abuse and dependency.  
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Chapter 6: General Discussion and Future Directions 
Taken together, the four studies comprising this dissertation examined the effects 
of acute and chronic drug administration on the NAcc shell and core, with particular 
emphasis on specific cellular circuits and synaptic plasticity potentially involved in drug 
abuse and dependence. Specifically, these studies focused first on the cholinergic 
interneurons of the NAcc shell, a region known to respond, metabolically, 
neurochemically and molecularly, during the initial stages of drug use. Despite the major 
role of the NAcc in drug administration studies, the specific contribution of the 
cholinergic interneurons of the NAcc has received little attention in the field of drug 
abuse and dependency. Therefore, the question addressed in the first study (chapter 2) 
was whether these neurons were involved following acute (i.e. first-time) drug 
administration. This study showed that these cholinergic interneurons were dose-
dependently activated following the acute self-administration of cocaine, specifically in 
the shell compartment of the NAcc, revealing a potential role for this particular cell 
population in drug abuse.  
The second and third studies (chapters 3 and 4) tested whether these cholinergic 
neurons expressed key excitatory (DA D5) and inhibitory (DA D2) receptor subtypes. 
Administration of drugs of abuse leads to changes in DA transmission within the NAcc 
following short and long-term drug treatment. Dopamine receptors are likely activated by 
drug-induced changes in extracellular DA levels, as well as drug-induced behavioral 
changes, such as cocaine-induced conditioned place preference (Graham et al., 2006). 
Although previous studies have shown that cholinergic cells in the NAcc express high 
levels of both DA D5 and DA D2 receptor mRNA, the localization of the receptor protein 
within this cell population was unknown. These studies localized both DA receptor 
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subtypes at specific locations along the cell bodies, dendrites and axons of cholinergic 
interneurons in the NAcc. The specific neuroanatomical localization of these receptors 
provided insight into two possible molecular substrates (i.e. DA D5 and DA D2 
receptors) mediating dopaminergic influences of ACh neurotransmission in the NAcc. 
Dopamine receptor neuroadaptations in the NAcc were also investigated, using a repeated 
2-week drug regimen, in rats trained to lever press for intravenous cocaine infusions (i.e. 
cocaine self-administration paradigm), but due to some limitations in the study (for 
example, animals did not self-administer enough cocaine), the findings proved 
inconclusive. Thus, the potential effects of repeated drug-treatment on DA D5 and DA 
D2 receptor neuroadaptations remain to be examined in a future study.  
Dopamine activation of cell surface receptors, following drug administration, 
leads to the induction of intracellular cascades, involving mechanisms (e.g. CREB, delta 
FosB, CDK5, etc.) which have been linked to persistent cellular and morphological 
changes in the brain, presumably underlying long-lasting drug-induced behavioral 
changes; however, changes in synapse number, as a result of repeated drug treatment, had 
not been directly examined. Therefore, the fourth study (chapter 5) investigated whether 
synaptic alterations occur in the NAcc following long-term drug treatment. This final 
study demonstrated, for the first time at the electron microscopic level, that chronic (4-
week) treatment with cocaine or morphine leads to synaptic rewiring in the NAcc, and is 
persistent following 3 weeks of drug-abstinence. More specifically, an increase in the 
number of excitatory synapses in the NAcc shell occurs with both psychostimulants and 
opiates, and similar synaptic reorganization occurs in the NAcc core specifically in 
cocaine-sensitized animals. Future work remains to determine more specifically whether 
the synaptic changes are a direct result of the drug administration itself or the combined 
effects of repeated drug treatment and drug abstinence. 
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In all, findings from these studies are in agreement with previous reports 
supporting a significant role for the NAcc as a key neuroanatomical substrate involved in 
acute and chronic drug administration, and further identify specific potential neural 
substrates and sites of synaptic plasticity. Additional studies are needed to examine the 
neuroadaptive effects of drug administration on DA receptor expression and long-lasting 
synaptic changes within cholinergic interneurons of the NAcc shell and core. Such 
studies, which elucidate the specific contribution of discrete cell populations in critical 
brain areas targeted by drugs of abuse, are rare, but are necessary for the development of 
more specific drug treatments aimed at combating drug abuse and dependence. 
Furthermore, evidence of drug-induced increases in the number of excitatory 
(presumably glutamatergic) synapses within the NAcc requires further investigation of 
possible sources of excitatory inputs, such as the PFC, hippocampus, amygdala, or 
thalamus. Similarly, the convergence of glutamatergic and dopaminergic inputs onto 
MSNs would more clearly address the question of the increasingly ambiguous role of DA 
in reward and reinforcement while shedding light on the combined effects of DA and 
glutamate in associative-learning mechanisms posited to underlie cellular processes in 
addiction. Such neuroadaptations, if examined in future studies, will aid in the 
development of new therapies and pharmaceutical treatments designed to combat 
persistent drug-induced behaviors, such as compulsive drug intake, tolerance, 
withdrawal, drug craving and relapse. 
6.1 Conclusion 
These studies show that cholinergic cells in the NAcc shell are involved in the 
initial stages of cocaine intake, and further suggest that DA D5 and D2 receptors 
expressed on these cells and their potential neuroadaptation can potentially mediate the 
response of these cells to drug-induced increases in DA neurotransmission in the NAcc; 
 129
however, direct evidence of a role for DA receptor neuroadaptation on cholinergic 
neurons in addiction remains to be examined. Furthermore, the final study provides the 
first ultrastructural evidence that 4 weeks of repeated cocaine (psychostimulant) and 
morphine (opiate) treatment followed by 3 weeks of abstinence leads to 1) an increase in 
the number of excitatory synapses in the NAcc shell and 2) cocaine sensitization, as 
measured by drug-induced stereotypic behaviors, is associated with an increase in the 
number of excitatory synapses in the NAcc core; however future work will determine 
whether the synaptic rewiring is due to the drug treatment itself or the combination of 
repeated drug administration followed by drug cessation. The specific mechanisms 
through which these drug-induced synaptic changes occur is not known; however, 
continued work on the molecular and cellular forms of neuroplasticity in conjunction 
with future synaptic and behavioral analyses will reveal additional information as to the 
key neuronal substrates underlying drug-induced changes in the brain and behaviors. 
Such studies are critical to the understanding, treatment and ultimate prevention of drug 
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